Published in final edited form as:

Free Radic Biol Med. 2016 November ; 100: 123–137. doi:10.1016/j.freeradbiomed.2016.04.012.

Mitochondrial control of cell bioenergetics in Parkinson's disease

Raquel Requejo-Aguilar¹ and Juan P. Bolaños^{2,*}

¹Department of Biochemistry and Molecular Biology, University of Cordoba, Institute Maimonides of Biomedical Investigation of Cordoba (IMIBIC), Cordoba, Spain

²Institute of Functional Biology and Genomics (IBFG), University of Salamanca-CSIC, Salamanca, Spain

Abstract

Parkinson disease (PD) is a neurodegenerative disorder characterized by a selective loss of dopaminergic neurons in the *substantia nigra*. The earliest biochemical signs of the disease involve failure in mitochondrial-endoplasmic reticulum cross talk and lysosomal function, mitochondrial electron chain impairment, mitochondrial dynamics alterations, and calcium and iron homeostasis abnormalities. These changes are associated with increased mitochondrial reactive oxygen species (mROS) and energy deficiency. Recently, it has been reported that, as an attempt to compensate for the mitochondrial dysfunction, neurons invoke glycolysis as a low-efficient mode of energy production in models of PD. Here, we review how mitochondria orchestrate the maintenance of cellular energetic status in PD, with special focus on the switch from oxidative phosphorylation to glycolysis, as well as the implication of endoplasmic reticulum and lysosomes in the control of bioenergetics.

Keywords

Parkinson's Disease; mitochondria; lysosome; autophagy; glycolysis; pentose-phosphate pathway; neurodegeneration; redox

1. Introduction

Parkinson's disease (PD) is a neurodegenerative disorder clinically characterized by motor deficits such as tremor, bradykinesia, rigidity and postural instability, eventually accompanied by non-motor complications such as dementia [1]. These symptoms are mainly associated with loss of dopaminergic neurons (DA) of the *substantia nigra* (SN). The mechanisms underlying DA death have been investigated in many cellular and animal models [2–7]. Mitochondrial dysfunction plays a key role in the development of PD [8, 9].

*Corresponding author, Juan P. Bolaños, Institute of Functional Biology and Genomics (IBFG), University of Salamanca-CSIC, Zacarias Gonzalez, 2, 37007 Salamanca, Spain. Phone: +34923294907, jbolanos@usal.es.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Damage of mitochondrial electron transport chain (ETC) affecting complex I, mutation of genes involved in mitochondrial function and defects in the regulation of mitochondrial dynamics has been widely reported in PD pathogenesis [10–13]. Being the main energy-producing organelles of the cell, mitochondria oxidize carbons obtained from carbohydrates and fat, producing ATP through the oxidative phosphorylation (OXPHOS) [14, 15]. Accordingly, any process impairing mitochondria may lead to metabolic switching aimed to compensate for their diminished ability to produce ATP. For instance, switching from OXPHOS to glycolysis is a well-known phenomenon in cancer –the Warburg effect [16]. Here, we address the notion that, similarly to cancer, PD is a metabolic-like disease. Actually, many PD-related genes are also altered in cancer, suggesting common mechanisms in both pathologies [17]. Thus, several epidemiological studies have reported an association between PD and cancer, although this link is yet controversial. Thus, whilst initially it was described an inverse correlation between PD and cancer vulnerability, a recent study reports a positive relationship, at least for certain cancer types, including skin, breast and brain cancer [18]. This odd association provides a new perspective to a well-known opposing cell fate of degeneration and death of post-mitotic neurons, and the uncontrolled division and enhanced resistance to death of cancer cells. An example of this is the loss of function of parkin (one of the genes altered in both PD and cancer). Thereby, parkin mutations results in the deficiency of E3 ligase activity leading to unfolded protein system (UPS) dysfunction and cyclin E build up. CDK2/cyclin E phosphorylates the tumour suppressor retinoblastoma releasing the transcription factor E2F-1 from inhibition. In mitotic cells E2F-1 up-regulates proteins that facilitate cell cycle progression, but in post-mitotic neurons E2F-1 triggers apoptosis through p53 and Bax [19, 20].

Mitochondrial dysfunction leading to metabolic shift and, eventually, neuronal death, may also be a consequence of decreased ability to clear the damaged mitochondria. This can lead to a positive loop of mitochondrial damage, as complex I inhibition, observed in PD and some PD experimental models, increases mROS formation that in turn can oxidize mitochondrial DNA (mtDNA) and other components of the ETC that contribute to oxidative stress [21]. Thus, defects in regulation of mitochondrial dynamics leading to mitochondrial dysfunction may also be involved in PD and, although the specific role of mitochondrial dynamics in PD pathogenesis remains unknown, both toxin and genetic models of PD show signs that interrelate them. Thus, toxins such as MPTP cause Drp1-dependent mitochondrial fragmentation and increased mitophagy in SH-SY5Y cells and dopaminergic neurons [22]. Rotenone, at high concentrations, induce mitochondrial fission and cell death in primary neurons, being this ameliorated by increased fusion or inhibited fission after overexpression of Mfn1 or inhibition of Drp1 [23]. In the case of genetic models, α -synuclein overexpression inhibits mitochondrial fusion by interaction with mitochondrial membranes leading to fragmented mitochondria [24, 25]. Loss of Parkin and Pink1 triggers increased vulnerability to mitochondrial damage in cells [10, 27, 28]. Under normal conditions, parkin protein is recruited in impaired mitochondria *via* a Pink1-dependent mechanism to induce mitophagy [29]. This process involves ubiquitylation of mitochondrial aberrant proteins for proteasomal degradation. Accordingly, the lack of function of Pink1 or Parkin leads to the accumulation of misfolded proteins, such as α -synuclein, which is accumulated in the PD brain. Furthermore, under normal conditions, PINK1 and Parkin promote fission and inhibit

fusion processes, hence the loss of either protein alters mitochondrial morphologies, producing Drp1-dependent mitochondrial fragmentation and decreasing the mitochondrial membrane potential and ATP production [30, 31]. Loss of DJ-1 in cortical neurons reduces fission and increase mitophagy, which is reverted by PINK1 and Parkin [26]. DJ-1 is also involved in the degradation of misfolded proteins, thus protecting from mitochondrial fragmentation after damage; it has been observed that Parkin, Pink1 and DJ-1 form a complex having E3 ligase activity [32]. However, many reports have shown that DJ-1 acts in parallel to, or up-stream of, the Pink1/Parkin pathway [33, 34]. DJ-1, *via* its Cys¹⁰⁶, may also act as a redox sensor protein exerting protection against oxidative stress [35]. Finally, LRRK2 also affects mitochondrial function and dynamics. Thus, aged transgenic mutant LRRK2 mice exhibit increased damaged mitochondria and mitophagy in cerebral cortex and cultured neurons. This may be mediated by Drp1 because LRRK2 interact with Drp1 enhancing its recruitment into mitochondria. However, this is yet controversial as it depends on the cell type, thus further studies still need to be done [36].

The endoplasmic reticulum (ER)-mitochondria crosstalk is critically important to preserve mitochondrial and cellular integrity. ER-mitochondria contact sites transfer Ca²⁺ from ER to mitochondria to sustain cell metabolism and bioenergetics [28, 37, 38]. Recent studies suggest PD to be linked to other metabolic diseases, such as diabetes or metabolic syndrome [39]. For instance, epidemiological evidence links type 2 diabetes mellitus (T2DM) with the pathogenesis of PD, since mitochondrial dysfunction and ER-stress leads to insulin resistance [40]. Interestingly, DJ-1 activity is reduced in both PD patients and patients with T2DM [41]. ER-stress alters protein folding leading to accumulation of α -synuclein to form the PD typical Lewy bodies cytoplasmic inclusions [42], as well as reduces insulin secretion in diabetes [43]. Inflammation, another key factor risk in PD [44, 45] is also observed in T2DM [46]. Insulin receptors are present in the *substantia nigra* [47] and impaired insulin signalling affects glucose uptake in this brain area and causes neuronal dysfunction by inactivating K_{ATP} channels [48]. High fat diets lead to insulin resistance and accelerate PD progression in a rodent model [49]. Lipids and ceramides, generated from saturated fatty acids, are antagonists of insulin activity, thus likely connecting insulin resistance with neurodegeneration [50]. Cytochrome P450, a typical liver enzyme that is regulated by the brain dopaminergic system in rodents, has been found damaged in PD patients [51, 52]. Finally, there are similarities in DJ-1 signalling pathways found in brain and pancreas [41].

In summary, there is a large body of evidence suggesting the occurrence of important links between glucose homeostasis and PD, being mitochondria a critical nexus. Here, we review this novel aspect of neurodegeneration with the aim to contribute shedding light on the search for future novel therapeutic strategies.

1.1 Dopaminergic neurons are particularly sensitive to metabolic imbalance

The dopaminergic neurons of the *substantia nigra pars compacta* (SNpc DA neurons) are highly energy demanding, a feature that is likely due to the metabolic sustaining of their unusually large axonal arborisation [6, 53]. Interestingly, by reducing the arborisation of the SNpc DA neurons using semaphorin-7A, OXPHOS activity and survival are decreased when exposed to the parkinsonian-like compounds MPP⁺ and rotenone [53]. mROS production in

the SNpc DA neurons is higher than in other neurons due to the dopamine oxidative metabolism, and takes place in the axon terminals, where the mitochondrial density is higher than in the ventral dopaminergic neurons [53, 54]. Iron content has been reported to be high in the SNpc DA neurons, which may be consequence of its enhanced release from ferritin caused by $O_2^{\bullet-}$, from haemoglobin and cytochrome c by peroxides, and/or from iron-sulfur proteins by peroxynitrite ($ONOO^-$). Thus, increased of metal ions such as Fe^{2+} enhance H_2O_2 conversion to $\bullet OH$ via the Fenton reaction, which amplifies oxidative stress [55]. Interestingly, iron-mediated oxidative stress can promote α -synuclein aggregation by catalysing α -helix conversion into β -sheet, which forms the partially-folded intermediates that are susceptible to aggregation [55]. Antioxidants, such as reduced glutathione and peroxiredoxin 5, are weakly synthesized in the SNpc DA neurons [55–57]. SNpc DA neurons pacemaking is dependent on a particular L-type voltage-dependent Ca^{2+} channels that leads to large Ca^{2+} influx and subsequent ATP-dependent extrusion, thus increasing ATP requirements and oxidative stress [58–61]; in fact, antagonists of this L-type channel are neuroprotective [59, 62]. Finally, 1-acetyl-6, 7- dihydroxyl-1, 2, 3, 4-tetrahydroisoquinoline (ADTIQ), a neurotoxin found in the brain of PD patients, is synthesized from a dopamine-derived tetrahydroisoquinoline (TIQ) and methylglyoxal, a major side product of glucose metabolism. Thus, glycolytic up-regulation after mitochondrial dysfunction, along with increased TIQ synthesis in DA neurons, could enhance the synthesis of ADTIQ, thus contributing to DA neuron degeneration [63]. Altogether, these observations suggest that the particular metabolism and morphology of SNpc DA neurons render them more vulnerable to perturbations of mitochondrial functions in response to multiple factors, such as gene mutations, environmental toxins, and aging.

2. Mitochondrial dysfunction, mROS and energetic metabolism in PD

ROS are continuously produced in all tissues, and their production and detoxification are tightly balanced. Shifting this balance enables ROS to activate intracellular signalling and/or generate oxidative stress, eventually inducing cell death. Oxidative stress is one of the hallmarks of PD, being the major sources of ROS the DA neurons [64–66]. Dopamine is an unstable molecule able to produce reactive quinones and free radicals by tyrosinase and monoamine oxidase (MAO)-catalysed auto-oxidation [67, 68]. Intra-mitochondrial iron overloading causes oxidative stress, since ferric and ferrous ions (Fe^{3+} , Fe^{2+}) can react with superoxide anion ($O_2^{\bullet-}$) and hydrogen peroxide (H_2O_2) to generate hydroxyl radicals through the Fenton reaction; these ROS synergize with dopamine oxidation to trigger neurotoxicity [69, 70]. Hydroxyl radicals generation and decreased glutathione contributes to ROS toxicity and neurodegeneration associated with PD [71]. Maintaining Ca^{2+} homeostasis requires ATP-dependent pumps [72], which increase the energy demand and OXPHOS activity, consequently leading to higher ROS generation. As above-mentioned, SNpc DA neurons express L-type Ca^{2+} channels for Ca^{2+} influx, which causes basal mitochondrial oxidative stress likely responsible for cell death acceleration [72].

PD is associated with chronic neuroinflammation, a phenomenon controlled by the brain microglial cells. Microglial activation has thus been observed in both sporadic and familial PD patients [73]. Microglial activation in turn leads to increased cytokine formation, ROS production and decreased secretion of trophic factors, inducing neuronal death [66, 74, 75].

Toxins, such as MPTP and rotenone, as well as mutations of PD-associated proteins like α -synuclein, Parkin, Pink1, DJ-1 and LRRK2, have been reported to activate glial cells and release ROS, inducing astrocyte activation thus amplifying the pro-inflammatory response and increasing microglial phagocytosis [76–79]. As already indicated, mitochondrial dysfunction triggers ROS formation [80]. Complex I and, to a smaller extent, complex III of the ETC are considered to be the main sites of mROS production [21]. Complex I inhibition results in enhanced ROS production, and excess ROS inhibit complex I. Inhibition of complex I activity is well known to occur in the SNpc of PD patients [81–83]. Environmental factors, such as MPTP or rotenone, as well as the loss-of-function of PD-related proteins such as Parkin, Pink1 or DJ-1, are known factors that inhibit complex I directly or indirectly, thus disrupting ATP synthesis and increasing ROS [84–88]. Interestingly, the alternative electron carrier methylene blue (MB), which accepts electrons from NADH and transfers them to cytochrome *c* thus bypassing complexes I–III, is able to increase cellular oxygen consumption and to reduce glycolysis in cultured cells, attenuating the toxicity of complex I inhibition by rotenone [89].

When mROS is produced in excess and OXPHOS is impaired, it is often observed a compensative enhanced glycolytic activity, thus suggesting that mROS and glycolysis interact during cell energy homeostasis [90]. For instance, in skeletal muscle and cultured cells, H_2O_2 stimulates glucose uptake [91–94]. Interestingly, in L6 myoblast, glucose uptake inhibition leads to increased ROS [95] and suggests a possible antioxidant-like role for glucose. Out of the 14 glucose transporter (GLUT) isoforms described so far [96], GLUT1 is up-regulated by ROS [97]. In fact, GLUT1 transcriptional expression is governed by transcription factors including hypoxia-inducible factor-1 (HIF-1) [98]. HIF-1 is composed by two subunits, α and β , being its activity mainly regulated through the stabilization of its α -subunit. Under normoxic conditions, the α -subunit is degraded by the proteasome, which requires hydroxylation on the Pro residues present in the O_2 -dependent degradation domain. During hypoxia, hydroxylation is inhibited hence HIF-1 α is stabilized, enabling the formation of a complex with HIF1 β that is translocated into the nucleus to promote the expression of several genes, including those encoding GLUT1 and enzymes of the glycolytic pathway [87, 99]. Interestingly, mROS also stabilize HIF1 α [87]. In muscle, GLUT1 activity is increased by 5'-AMP-activated protein kinase (AMPK) [100], a protein kinase that is activated by LKB1-mediated phosphorylation during elevated AMP/ATP ratio or mROS [101–103]. Both HIF1 and AMPK activation leading to increased glucose uptake has been observed in PD models [87, 104]. GLUT1 activity can also be increased by translocation to the plasma membrane, which takes place through a ROS-mediated oxidation of key sulfhydryls in the Ataxia Telangiectasia Mutated (ATM) protein forming an active dimer [105, 106]. ATM is localized close to the mitochondria, suggesting that its dimerization is mediated by mROS [107].

Glucose metabolism can play a role in regulating the ROS production and scavenging balance. For instance, glucose oxidation through the pentose phosphate pathway (PPP) produces reducing equivalents in the form of NADPH, which is necessary to recycle antioxidant glutathione from its oxidised status [108]. This is especially important in neurons because they are more vulnerable to oxidative stress than other cell types. In neurons, the limiting glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-

bisphosphatase-3 (PFKFB3) is continuously degraded by the proteasome, and this is why they preferentially metabolize glucose via the PPP instead glycolysis, in contrast to what happens with other cells with more robust antioxidant system [109]. Thus, inhibiting glucose flux through the PPP increased levels of oxidative stress and neuronal death [109]. In addition, certain stimuli are able to stabilize PFKFB3, switching from PPP to glycolysis [110]. This leads to increased oxidative stress and apoptotic neuronal death that counteract with overexpression of glucose-6-phosphate dehydrogenase, the rate-limiting enzyme of the PPP. Both increased glycolysis and decreased PPP were shown to be abolished by siPFKFB3 indicating that both metabolic pathways are fully controlled by this protein [110]. Thus, proteasome dysfunction during the loss of Parkin or other PD-related proteins would likely stabilize PFKFB3 leading to a switch from PPP to glycolysis and oxidative stress. Interestingly, a down-regulation of PPP rate-limiting enzymes has been documented in post-mortem brain samples of PD patients [111], strongly supporting the hypothesis that PPP disruption may be an important factor in the pathogenesis of PD [111, 112] and aging [112].

3. Implications of mitochondrial quality control for metabolism in PD

Failure in the mitochondrial quality control mechanisms impairs the mitochondrial ability to generate energy by OXPHOS, which can invoke glycolysis as an attempt to maintain cellular ATP (Fig. 1). Mitochondrial quality control mechanisms require communication between mitochondria and other organelles, including the ER and lysosomes, as disruption of this process has been observed in PD and other neurodegenerative disorders such as Gaucher disease (GD) [113].

3.1 Mitochondria-lysosome crosstalk

Mitochondrial dysfunction in neurodegenerative diseases involves alterations in the mitochondrial quality control mechanisms [114–116]. Mitochondrial turnover mainly occurs by autophagy, a process requiring functional lysosomes. Lysosomes are critical for protein and organelles degradation [117], calcium signalling [118, 119], endocytic processes [120], and nutrient sensing [121]. During autophagy, lysosomes fuse with autophagosomes to promote degradation of engulfed organelles and proteins. The membrane origin of autophagosome remains unclear; some studies suggest that they are generated “de novo”, whereas other studies suggest that they arise from other organelles such as ER or mitochondria [122]. The process is initiated by activation of Vps34 and its interaction with Beclin-1. This is produced only if the anti-apoptotic protein Bcl2 is phosphorylated and dissociated from Beclin-1, indicating a link between autophagy and apoptosis [122]. After maturation, autophagosome fuses with the lysosome to form the autophagolysosome, in which organelles and/or misfolded proteins are degraded and recycled. Thus, failure in these processes may lead to the accumulation of aberrant mitochondria and misfolded proteins, which are hallmarks of PD. In addition, mutations in genes encoding lysosomal proteins cause lysosomal storage diseases (LSDs), which are accompanied by the accumulation of damaged mitochondria. Actually, failure in lysosomal function seems to be an event occurring earlier than mitochondrial damage [123]. Amongst other substrates, α -synuclein is aggregated [124]. Mutant α -synuclein tightly binds to the lysosomal membrane to inhibit the autophagy-lysosome pathway, resulting in degradation of wild type α -synuclein [116].

Besides PD, α -synuclein aggregates are also observed in GD, the most common of the LSDs caused by recessive mutations in glucocerebrosidase (GBA). Thus, GD and PD have similar hallmarks including loss of DA neurons of SNpc, α -synuclein accumulation, tremor, bradykinesia and rigidity. In addition, mitochondrial membrane potential (ψ_m) collapse and mitochondrial complex I-derived ROS-mediated ETC damage also occur [113, 122].

3.2 ER-mitochondria tethering

Mitochondria and ER are tightly interconnected, both physically and functionally. ER-mitochondria contact sites, known as mitochondria-associated membranes (MAMs) [125], facilitate Ca^{2+} and lipid transfer between these organelles, acting as platforms for signals regulating cell death and survival mechanisms [126–129]. Mitochondrial Ca^{2+} levels regulate ATP synthesis by activating tricarboxylic acid (TCA) dehydrogenases [130] and ATP synthase [131, 132]. However, mitochondrial Ca^{2+} also triggers apoptotic cell death [133, 134] through mechanisms that take place at the ER-mitochondria interface. Disruption of normal ER function leads to misfolded and unfolded protein accumulation in the ER, a process known as the unfolded protein response (UPR) that is an adaptive cellular response to ER stress aimed to restore ER homeostasis [135]. Interestingly, UPR includes changes in metabolism focused to provide metabolic support for the cellular adaptation. Thus, the increase in ER-mitochondrial contact sites leads to an increase in mitochondrial Ca^{2+} uptake, mitochondrial metabolism and ATP production [136]. On the contrary, disruption of ER-mitochondrial contacts, or blockage of Ca^{2+} transfer, increases cell death in response to ER stress [135, 136]. Thus, although ER-mitochondria contacts are beneficial in early stages of ER stress, these contacts lead to cell death if stress is maintained for long periods of time by Ca^{2+} overloading.

ER-mitochondrial contact sites are important for cell signalling. Thus, MAM are involved in insulin signalling [137], as several components of the insulin cascade, such as Akt and mTORC2, have been found at the MAM [137–139]. Inhibition of mitochondrial Ca^{2+} uptake, in skeletal muscle cells and cardiomyocytes, reduces insulin-dependent Akt phosphorylation, GLUT4 membrane translocation, and glucose uptake [140, 141]. Obesity in mice is accompanied by an increase in MAM and Ca^{2+} overloading, suggesting a pathophysiological role of MAM in insulin resistance and T2DM [142]. MAM disruption may also be involved in neurodegeneration, particularly in PD, since Parkin, Pink1, DJ-1 and α -synuclein are present in the ER-mitochondrial contact sites to support Ca^{2+} transfer. For instance, α -synuclein mutations decrease the number of ER-mitochondria contact sites, causing ER stress and mitochondrial fragmentation [37]. Thus, ER-mitochondria tethering is disrupted in both T2DM and PD, further suggesting a link between these disorders.

4. Metabolic disturbances in sporadic models of PD

As above mentioned, mitochondrial complex I damage has been shown in post-mortem brains, skeletal muscle, platelets and lymphocytes of PD patients [81, 143–147]. Inhibitors of complex I activity, such as methyl-4-phenylpyridinium (MPP^+) and rotenone induce mitochondrial dysfunction in dopaminergic cells [148]. Likewise, 6-hydroxydopamine (6-OHDA) is used as a dopamine analogue to induce ROS-associated degeneration of SNpc DA

neurons [149]. Since MPP⁺, rotenone and 6-OHDA are widely used to model the dopaminergic neuronal death of PD, both in cultured cells and in experimental animals, we revisit the metabolic disturbances found in several chemical models of PD.

4.1 MPP⁺

MPP⁺, the bioactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), causes a clinical picture similar to PD syndrome in humans and non-human primates, being widely used to investigate therapeutic strategies [150, 151]. Thus, MPTP is metabolized in the brain in astrocytes, by monoamine oxidase-B, to MPP⁺, which is released to the extracellular space and taken up by dopaminergic neurons through the dopamine transporter (DAT) [152]. MPP⁺ is accumulated in mitochondria where it inhibits complex I [151, 153, 154]. Consequently, OXPHOS is blocked and neurons become dependent on glycolysis for ATP production. Thus, by increasing the rate of glycolysis, neurons could compensate for the mitochondrial deficiency in ATP synthesis and hence to meet the cell energy demands [155, 156]. In fact, it has been found that maintaining cell ATP concentrations *via* glycolysis attenuates MPP⁺-induced toxicity [157]. On the contrary, a glucose-deficient environment exacerbates MPP⁺-induced toxicity [158]. Studies in neuroblastoma cells and in rat brain indicate that glucose prevent MPP⁺ toxicity by attenuating ATP depletion without recovering mitochondrial respiration, hence indicating increased glycolysis [159, 160]. Interestingly, at MPP⁺ concentrations below 1 mM, its toxicity depends of glucose depletion; however, at MPP⁺ concentrations between 1 and 10 mM, cells undergo a metabolic collapse with a switch from OXPHOS to glycolysis that leads to cell death [159]. Thus, the mechanism of MPP⁺ toxicity is biphasic, namely (i) the DAT-mediated mechanism selective for dopaminergic neurons (at low concentrations) and (ii) the oxidative mechanism that occur a higher concentrations [160]. In SH-SY5Y and differentiated human neural progenitor ReNcell VM cells, microRNA-7 increases the neuronal expression of GLUT3 through targeted repression of RelA, which promotes glycolysis as evidenced by increased glucose consumption and lactate release, increased ATP and prevention against low dose MPP⁺-induced cell death [161].

4.2 Rotenone

Rotenone, initially used as an insecticide and fish poison, increased PD incidence in farming communities exposed to this compound [162]. Rotenone crosses the blood brain barrier and plasma membranes due to its hydrophobicity. DA neurons are particularly susceptible to rotenone-induced degeneration [163]. *In vitro* and *in vivo* exposure to rotenone induces both soluble and insoluble α -synuclein aggregates, increased caspase activation and apoptosis [164–166]. Inhibition of complex I and cellular respiration by rotenone results in the compensatory induction of glycolysis, loss of bioenergetics reserve capacity, activation of apoptotic pathways, and cell death [167]. Rotenone decreases maximal respiration and reserve capacity at doses that MPP⁺ increases this reserve capacity, indicating that both compounds act a different level of the ETC; while rotenone inhibits complex I, MPP⁺ inhibits both complex I and ATP synthase or related [167]. However, rotenone shows a mechanism of action other than solely ETC disruption leading to ROS production [168], since it induces glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression and nuclear and mitochondrial translocation. Accumulated GAPDH promotes intermolecular

disulphide bonding resulting in the formation of intracytoplasmic aggregates of GAPDH, which may contribute to the formation of inclusion bodies, such as Lewy bodies, and neuronal apoptotic death [169].

4.3 6-Hydroxydopamine (6-OHDA)

6-OHDA, the hydroxylated analogue of dopamine, has been found in human brain and urine from PD patients treated with L-dopa [170, 171]. 6-OHDA reversibly inhibits the activities of complexes I and IV in rat brain mitochondria [172], although it also induces degeneration of SNpc neurons by oxidative damage *via* auto-oxidation, which forms reactive quinones that generate hydrogen peroxide and superoxide [173]. 6-OHDA reacts with Fe^{3+} causing its release and subsequent cellular damage [174]. This is particularly relevant for PD pathogenesis since SNpc DA neurons contain higher iron levels associated to neuromelanin [175, 176]. Differentiated SH-SY5Y treated with 6-OHDA do not show, however, OXPHOS inhibition, thus 6-OHDA likely impacts on mitochondrial redox signalling rather than on bioenergetics [167]. However, the oxidative stress produced by 6-OHDA indirectly causes mitochondrial dysfunction, which leads to glycolysis up-regulation [177].

4.4 Paraquat

The herbicide paraquat (1,1'-dimethyl-4,4'-bipyridinium dichloride) is structurally similar to MPTP, and it has been associated with PD [162, 178]. Paraquat causes selective and-dose dependent loss of SNpc DA neurons [179, 180]. It is unlikely that paraquat inhibits complex I, but it produce ROS [181] both *in vitro* and *in vivo* by multiple mechanisms, including redox cycling [182, 183] and nitric oxide synthase activity [184]. Thus, the mechanism whereby paraquat exerts neurotoxicity is different from those used by MPP^+ , rotenone or 6-OHDA [177]. Using a combined metabolomics approach by nuclear magnetic resonance (NMR) and direct-infusion electrospray ionization mass spectrometry (DI-ESI-MS), it has been revealed that human dopaminergic neuroblastoma cells exposed to paraquat presented deeper alteration in PPP metabolome. Thus, metabolites of PPP such as glucose-6-phosphate, fructose-6-phosphate, glucono-1,5-lactone, and erythrose-4-phosphate have been found increased after paraquat treatment, an effect that was accompanied by inhibition of glycolysis and TCA cycle activity. In addition, increased expression of glucose-6-phosphate dehydrogenase (G6PD), which supplies NADPH, was observed with paraquat. These findings have led to the proposal that increased PPP, by enhancing NADPH levels, would be necessary for paraquat redox cycling causing oxidative stress [177].

5. Metabolic disturbances in genetic models of PD

During the last two decades, several genetic mutations have been found to be associated with familial forms of PD with similar clinical and pathological features of those in idiopathic PD [185–187]. The study of the proteins encoded by these genes has revealed the close link with mitochondrial function and metabolism, thus providing important insight about the molecular pathways and mechanism that may underlie neurodegeneration in PD.

5.1 α -synuclein

Mutations such as A530T, A30P and E46K, as well as duplication or triplication of the α -synuclein gene (PARK1, SNCA) have been associated with autosomal dominant PD [188–191]. α -synuclein is a hydrophobic protein prone form the typical fibrillar aggregations observed in Lewy bodies, which links this protein with both sporadic and familial forms of PD [42]. α -synuclein aggregation inhibits mitochondrial complex I activity, elevates ROS production [192] and increases protein-carbonyl levels [193]. *In vitro*, the interaction of α -synuclein with mitochondria leads to cytochrome *c* release, enhances mitochondrial Ca^{2+} , and triggers oxidative modifications of mitochondrial components [194]. These findings suggest an interrelation between protein aggregation and mitochondrial dysfunction, granting to α -synuclein a role as a modulator of oxidative stress. α -synuclein increases with ageing along with a loss of tyrosine hydroxylase-positive neurons [195, 196]. The accumulation of unfolded/misfolded α -synuclein leads to ER stress, which activates UPR [197] and correlates with markers of the UPR pathways protein kinase RNA-like ER kinase (PERK) and activating transcription factor-6 (ATF6), as well as its downstream pro-apoptotic CCAAT/enhancer-binding protein homologous protein (CHOP) [197]. Overexpression of the ER chaperone, glucose regulated protein 78 (GRP78/BiP), decreases α -synuclein toxicity by down-regulating ER stress mediators [197]. Such an ER stress response reprogramming prevents DA neurons death, reinforcing the key role of ER in PD neurodegeneration. In addition, α -synuclein is also present in MAM [37], hence connecting ER and mitochondria to regulate Ca^{2+} homeostasis and cholesterol metabolism [125, 127, 198]. Mutated α -synuclein reduces its association with MAM concomitantly with a decrease in ER-mitochondria juxtaposition and increased mitochondrial fragmentation. Overexpression of the mitochondrial fusion protein MFN2 or inhibition of the mitochondrial fission protein Drp1 do not revert such phenotype, indicating that α -synuclein acts downstream of the mitochondrial fusion/fission machinery [37].

Besides the above-mentioned functions linked to mitochondrial dysfunction, α -synuclein directly alters carbohydrate and lipid metabolism. Using a mouse model of PD that express the mutant form of human α -synuclein A53T, it has been observed that a high caloric diet induces a metabolic phenotype similar to that of the PD patients; this consists of a reduction of total and visceral body fat, hypoleptinemia, and increased energy expenditure without insulin resistance [199]. α -synuclein, which is present in pancreatic β -cells, down-regulates insulin secretion by interacting with K_{ATP} channels; however, if over-expressed, or expression of the mutant α -synuclein, results in excessive inhibition of insulin secretion contributing to diabetes, generating cellular stress and apoptosis resembling PD [200]. In contrast, α -synuclein ablation exacerbates insulin resistance in mouse adipose tissue and skeletal muscle, as well as in patients with low α -synuclein blood levels and increased insulin resistance [201]. In the adipose tissue and skeletal muscle of α -synuclein knockout mice, it has also been observed an increase in GLUT4-driven glucose uptake through an insulin-independent mechanism [202].

5.2 Parkin

Mutations in Parkin (PARK2) gene produce autosomal-recessive juvenile PD [203, 204]. As an E3 ubiquitin ligase involved in the proteasomal degradation of several substrates, loss of

Parkin causes accumulation of potentially toxic protein aggregates eventually involved in PD pathogenesis [205]. Parkin is confined to mitochondria, where it binds transcription factors such as the mitochondrial transcription factor TFAM [206]. Parkin prevents cytochrome *c* release [207] and α -synuclein aggregation, thus protecting mitochondria and attenuating DA neuronal loss [208]. In contrast, loss of Parkin impairs complex I and IV activities both in humans and mice, leading to mitochondrial respiration impairment and oxidative stress [86, 209]. Parkin loss also increases toxins sensitivity [210, 211] and disturbs mitochondrial dynamics and autophagy [29, 212]. Thus, Parkin participates in mitochondrial fission and fusion processes, mitochondrial transport, and removal of damaged mitochondria through mitophagy *via* a mechanism dependent on Drp1 [29, 213–215]. The triggering mechanism of Parkin-dependent mitophagy is the loss of mitochondrial membrane potential (ψ_m), which activates its recruitment to the mitochondria through PINK1 (see section below).

Parkin mRNA and protein levels increase during ER stress *via* the UPR pathway transcription factor ATF4, which binds the CREB/ATF elements in the Parkin promoter to increase its expression, thus preventing ER stress-induced mitochondrial damage and cell death [216]. In HeLa and neuroblastoma cells, Parkin favours ER-mitochondria contacts and the transfer of Ca^{2+} from ER to mitochondria, thus activating ATP synthesis [217]. Parkin has also a role in fat uptake [218]. Parkin knockout mice display lower weight gain preceding the mitochondrial and neurological abnormalities, which is more evident under a high-fat diet [86, 218]. Thus, a high fat diet to wild type mice induces Parkin levels in several tissues favouring fat uptake *via* mono-ubiquitylation, leading to stabilization, of the CD36 fatty acid translocase [218]. These results suggest that diet would be an interesting factor to consider for delaying the onset, or reduce the risk, of PD.

Parkin is a target of p53 and a potential tumour suppressor [219]. Thus, p53 induces *Parkin* gene transcription, in humans and mice, to mediate the p53 effects on glucose metabolism and antioxidant defence. Accordingly, loss of Parkin increases glucose uptake, glycolysis and lactate production, and reduces mitochondrial respiration. In addition, Parkin loss down-regulates the expression of several mitochondrial proteins, such as pyruvate dehydrogenase (PDHA1), which catalyses pyruvate conversion to acetyl-CoA in the mitochondria. This triggers a Warburg effect that can be restored by over-expressing Parkin [219]. Such a Warburg effect has also been linked with other functions of Parkin, such as mitophagy [220], mitochondrial dynamics [221] and genome integrity [222]. It should be mentioned that the regulation between Parkin and p53 differs depending on the cell line or tissue [219]. Nevertheless, it seems well established that loss of Parkin induces a Warburg effect contributing to the development of tumours by facilitating cell proliferation [223–225].

5.3 PINK1

PINK1 (PTEN-induced putative kinase; PARK6) mutations are, after Parkin, the second most common cause of early onset autosome recessive PD [226]. PINK1 is a serine/threonine kinase that is stabilized upon ψ_m collapse into the mitochondria [227], where it recruits Parkin from the cytosol [10, 29]. PINK1 knockdown in human dopaminergic neurons and mouse primary neurons causes morphological changes in mitochondria, decreased ψ_m , high ROS production and apoptosis [228, 229]. Whilst loss of PINK1 in

mice decreases complex I and IV activities and impairs mitochondrial respiration, it can also exacerbate mitochondrial respiration when exposed to H₂O₂ or mild heat shock [230]. PINK1 prevents cytochrome *c* release from mitochondria and apoptotic neuronal death [231, 232], and protects against MPTP-mediated oxidative stress [233].

PINK1 controls mitochondrial dynamics, hence being essential in energy metabolism maintenance, mitochondrial quality control, and cell viability [234, 235]. PINK1 promotes mitochondrial fission by inducing Drp1, and inhibits mitochondrial fusion by down-regulating mitofusins (MFN1 and MFN2) [214, 221, 236]. Parkin recruitment by PINK1 participates in the mitochondrial quality control process by triggering mitophagy [29, 212, 220]. A subpopulation of mitochondrial-derived vesicles (MDVs) requires Parkin and PINK1 to be formed. MDVs mediate the transport of mitochondria to lysosomes for the degradation of oxidized cargo proteins, thus regulate mitochondrial quality control under mild stress; however, failure of this protective system causes irreversible mitochondrial damage leading to mitophagy [237].

As most PD-related proteins, Parkin and PINK1 are present in MAM. PINK1 is involved in the regulation of ER-mitochondria Ca²⁺ transfer by increasing ER-mitochondrial contact sites [238]. As above-mentioned, Ca²⁺ transfer is essential for mitochondrial respiration and normal cell bioenergetics. In PINK1 deficient cells, Ca²⁺ homeostasis is a controversial matter. In neurons, PINK1 regulates Ca²⁺ efflux from mitochondria through Na⁺/Ca²⁺ exchanger, and PINK1 loss results in Ca²⁺ overload, inhibition of glucose transporter, and respiration impairment [239]. However, other studies report impaired respiration and increased glycolytic activity in myocytes and neurons from PINK1 knockout mice [239]. Glucose uptake is impaired in PINK1-deficient pancreatic β -cells, which produce an increase in intracellular Ca²⁺ and insulin secretion under low glucose conditions resulting in glucose tolerance *in vivo* [240]. Myocytes, which have higher ATP producing capacity and ψ_m , can buffer cytosolic Ca²⁺ rendering these cells resistant to Ca²⁺ stress [241]. Knockout and knockdown mouse neuroblastoma and embryonic fibroblasts (MEFs) for PINK1 showed reduced mitochondrial Ca²⁺ uptake and impaired mitochondrial ATP synthesis, leading to Ca²⁺ efflux [28]. In other studies performed in MEFs and primary cultured neurons from PINK1 knockout mice, mitochondrial deficiency leads to increased glycolysis with lactate release, along with increased glucose uptake leading to a Warburg-like effect through HIF1 α stabilization [87, 242].

PINK1 was identified originally because of its tumour suppressor action [243]. However, whether loss of PINK1 represses or enhances cell proliferation is yet controversial. Thus, PINK1 is induced by the tumour suppressors PTEN and FOXO3a, and it is associated with Beclin-1, which is a tumour suppressor [243–245]. In addition, PINK1 acts upstream of Parkin, which is a tumour suppressor through interaction with p53 [219]. Furthermore, *PINK1* gene is located in a region of chromosome 1p36 that contains tumour-suppressive activity [246]. In contrast, PINK1 is necessary for optimal activation of the oncogenic pathway IGF1/Akt, which indicates pro-oncogenic functions [247]. As indicated above, PINK1 is essential for mitochondrial dynamics, Ca²⁺ homeostasis and mitophagy, which are processes related to the cell cycle regulation [248–252]. MEFs isolated from PINK1 knockout mice show altered cell cycle, with cells multinucleated arrested in G2/M phase and

a decreased number of cells in G0/G1 [253]. This leads to a reduction in cell proliferation and an increase in mitochondrial fission according to the high levels of Drp1 observed [253]. However, in another study using identical PINK1 knockout cells, the opposite result was found, i.e., the proportion of cells in G2/M phase increased and the proportion of cells in the G0/G1 phase decreased, leading to enhanced cell proliferation rate concomitant with a higher glycolytic rate [87]. In this study, the rate of glycolysis was found to be essential for cell proliferation, since the inhibitor 2-deoxyglucose abrogated it. Moreover, the increase in the glycolytic rate was mediated by HIF1 α , as silencing of this transcription factor reverted both the increase in glycolysis and in cell proliferation [87]. Interestingly, in this study PINK1 knockout mice primary neurons were also used, in which it was observed a shift from PPP to glycolysis that led to apoptosis [87]. Thus, PINK1 loss of function may have dual consequences, cell proliferation or apoptosis, depending on the cell type and the environmental factors. Thus, whilst the cell cycle effects of PINK1 deficiency may be responsible for cancer, it may also be involved in neurodegeneration, since the abortive cell cycle re-entry is mechanistically linked to the death of post-mitotic neurons [254–257].

5.4 DJ-1

Mutations in *DJ-1* (*PARK7*) gene causes autosomal recessive early onset parkinsonism [258]. DJ-1 is a multifunctional protein that under basal conditions is mainly localized in the cytosol. However, upon oxidative stress, DJ-1 translocates to the mitochondria and later to the nucleus to exert its neuroprotective function [259–261]. Nuclear translocation of DJ-1 occurs by oxidation of the Cys¹⁰⁶ that acts as a redox sensor [259, 262]. Neurons and MEF defective in DJ-1 show decreased complex I activity and mitochondrial respiration [88, 263], along with increased oxidative stress accompanied by enhanced glycolysis [33]. MEF knockout for DJ1 show decreased ψ_m and increased mitochondrial permeability transition pore [264]. In neurons, DJ-1 knockdown causes ER stress, inhibition of the proteasome, and increased cell death [265, 266]. Cell models from human and mouse knockouts for DJ-1 show altered mitochondrial morphology and accumulation of defective mitochondria [267]. In addition, DJ-1-deficient mice show SNpc DA neuronal loss, elevated DA levels and enhanced DA re-uptake [268]. In these cells, DJ-1 loss sensitizes them against toxins such as MPTP and paraquat, while its overexpression protects them [269, 270]. All these effects can be reversed either by over-expressing DJ-1 or by antioxidant treatment, suggesting a key role for DJ-1 in antioxidant signalling. On the other hand, DJ-1 fosters the communication between RE and mitochondria [238], hence reducing DJ-1 levels causes mitochondrial fragmentation and decreased mitochondrial Ca²⁺ uptake. In HeLa cells, overexpression of p53 impairs the transfer of Ca²⁺ from ER to mitochondria increasing mitochondrial fragmentation; this was reversed by DJ-1 overexpression rescuing the ER-mitochondria contact sites, but not by Drp1 inhibition, indicating that mitochondrial fragmentation was independent of Drp1 activation [38]. Thus, besides its antioxidant role, DJ-1 participates in the maintenance of mitochondria integrity by improving ER-mitochondria communication.

DJ-1 is involved in glucose homeostasis. Thus, DJ-1 expression can be regulated under hyperglycemic conditions *in vitro* and *in vivo* [271, 272]. DJ-1 expression is increased under non-diabetic conditions in human and mouse islets during aging to prevent oxidative stress and to maintain the mitochondrial integrity that is necessary for glucose-stimulated insulin

secretion. Interestingly, decreased DJ-1 expression is observed in PD patients and in patients suffering from T2DM, indicating the interrelation between these diseases [41]. In addition, DJ-1 has been shown to transcriptionally co-activate PINK1 expression by binding to FOXOa3; accordingly, DJ-1 loss causes decreased complex I activity and increased glycolysis *via* regulating PINK1 [33]. Similar effects on glucose metabolism take place in DJ-1 knockout mouse skeletal muscle, where a higher energy expenditure, AMPK activation, and uncoupled mitochondrial respiration has been observed leading to a Warburg-like metabolic reprogramming [273]. In good agreement with the view that the Warburg effect may favour cell proliferation, loss of DJ-1 increases cell proliferation *via* regulating PINK1 [33].

5.5 LRRK2

Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are the most common genetic cause of PD and cause both autosomal dominant and sporadic PD [274, 275]. Several LRRK2 mutations showing gain-of-function cause apoptotic neuronal death that can be attenuated by inhibition of mitochondrial-dependent caspases, suggesting mitochondrial dysfunction in LRRK2-mediated pathogenesis [276]. In cortical neurons, LRRK2 mutations increase ROS and impair mitochondrial morphology and dynamics [277]. LRRK2 interacts with Dynamin like protein 1 (DLP1) in neurons, and expression of LRRK2 leads to translocation of DLP1 from the cytosol to the mitochondria, suggesting a functional role of LRRK2 in mitochondrial dynamics [277]. Mitochondrial elongation and interconnectivity are also altered in patients with LRRK2 G2019S mutation, indicating that LRRK2 is related to mitochondrial morphology maintenance. Skin biopsies obtained from this LRRK2 mutant PD patients also showed ψ_m collapse and ATP depletion [278]. These findings, together with the fact that LRRK2 is located in mitochondria [279, 280], suggest that mutant LRRK2 toxicity is linked to mitochondrial damage. Interestingly, the G2019S LRRK2 knock-in mouse shows transcriptional down-regulation of OXPHOS genes and up-regulation of glycolytic genes; furthermore, this mutant mouse down-regulates ubiquitylation and trafficking of proteins, suggesting that the accumulation of aberrant proteins and ER failure may underlie the OXPHOS-glycolysis shift [281].

5.6 Other relevant genetic mutations

Genome-wide association (GWAs) studies have revealed the occurrence of novel PD relevant loci [282]. For instance, ATP13A2 encodes a lysosomal transmembrane protein that belongs to the 5P-type ATPase subfamily [283], the mutations of which are associated with PD. ATP32A2 inhibition impairs the lysosomal ability to degrade certain proteins, including α -synuclein, by the autophagosome [284, 285]. Furthermore, mutant ATP13A2 causes ψ_m collapse, ATP depletion, reduced mitophagy, and increased ROS, which can contribute to neurodegeneration [286–288]. Similar biochemical signs have been found with the mutant PLAG6, another PD-related protein with calcium-independent phospholipase A₂ activity [289]. Finally, GIGYF2 loss of function causes neurodegeneration linked to insulin signalling impairment [290].

6. Conclusions and perspectives

PD is a complex pathology with both genetic and environmental components. Regardless its specific cause, mitochondrial redox and energetic failure are essential pathogenic mechanisms in which an intact mitochondrial communication with ER and lysosomes are important. Failure in this communication increases misfolded proteins and impairs Ca^{2+} transfer, which accelerates dopaminergic cell death by defective mitochondria accumulation. Increased ROS, a key hallmark of this disorder, is linked to a metabolic OXPHOS-glycolysis shift aimed to maintain ATP, minimize mROS production and prevent apoptotic death. Mutant genes, such as α -synuclein, Parkin, PINK1 or DJ-1, cause excess mROS that are relevant for the SNpc DA neurons, which show a particularly high oxidative metabolism. Importantly, prolonged oxidative stress can trigger irreversible damage to mitochondria leading to a bioenergetics failure that cannot be compensated by increased glycolysis (Fig. 1). Since under normal conditions glucose utilization *via* the PPP is an essential antioxidant mechanism for neurons, an increased glycolysis aggravates neuronal oxidative stress in PD. In addition, the OXPHOS-glycolytic shift facilitates cell proliferation, which may explain the link between PD and some tumour development, but also neurodegeneration due to a possible aberrant cell cycle re-entry of post-mitotic neurons. Finally, besides the nervous system, other tissues affected in PD, such as the liver and pancreas, show important metabolic alterations including those related with insulin secretion and impaired glucose uptake, which may link diet habits with T2DM in PD. Thus, loss of the mitochondrial control of bioenergetics appears to be behind the causes of this metabolic syndrome-like picture in PD. This may provide clues when designing novel future therapeutic strategies against PD.

Acknowledgments

J.P.B. is funded by the MINECO (SAF2013-41177-R; RTC-2015-3237-1), the ISCIII (RD12/0043/0021), the EU SP3-People-MC-ITN program (608381), the EU BATCure grant (666918), the NIH/NIDA (1R21DA037678-01).

Abbreviations

6-OHDA	6-hydroxydopamine
ADTIQ	1-acetyl-6, 7- dihydroxyl-1, 2, 3, 4-tetrahydroisoquinoline
AMPK	5'-AMP-activated protein kinase
ATF	activating transcription factor 6
ATM	ataxia telangiectasia mutated
CHOP	CCAAT/-enhancer-binding protein homologous protein
DA	dopamine
DAT	dopamine transporter
DI-ESI-MS	direct-infusion electrospray ionization mass spectrometry

PFKFB3	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3
G6PD	glucose-6-phosphate dehydrogenase
GAPDH	glyceraldehyde-3-phosphate dehydrogenase
GBA	glucocerebrosidase
GD	Gaucher disease
GLUT	glucose transporter
GRP78/BiP	glucose regulated protein 78
HIF-1	hypoxia inducible factor 1
LSDs	lysosomal storage diseases
MAMs	mitochondrial-associated membranes
MB	methylene blue
MDVs	mitochondrial-derived vesicles
MPP⁺	methyl-4-phenylpyridinium
MPTP	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Paraquat	1,1'-dimethyl-4,4'-bipyridinium dichloride
PD	Parkinson's disease
PDHA	pyruvate dehydrogenase
PERK	protein kinase RNA-like ER kinase
PINK1	PTEN-induced putative kinase 1
PPP	pentose phosphate pathway
SN	substantia nigra
SNCA	α -synuclein gene
T2DM	type 2 diabetes mellitus
TIQ	tetrahydroisoquinoline
UPR	unfolded protein response

References

1. Dawson TM. New animal models for Parkinson's disease. *Cell*. 2000; 101:115–118. [PubMed: 10786830]
2. Duan W, Mattson MP. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. *Journal of neuroscience research*. 1999; 57:195–206. [PubMed: 10398297]

3. Kim TW, Cho HM, Choi SY, Suguira Y, Hayasaka T, Setou M, Koh HC, Hwang EM, Park JY, Kang SJ, Kim HS, Kim H, Sun W. (ADP-ribose) polymerase 1 and AMP-activated protein kinase mediate progressive dopaminergic neuronal degeneration in a mouse model of Parkinson's disease. *Cell death & disease*. 2013; 4:e919. [PubMed: 24232095]
4. Mejias R, Villadiego J, Pintado CO, Vime PJ, Gao L, Toledo-Aral JJ, Echevarria M, Lopez-Barneo J. Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2006; 26:4500–4508. [PubMed: 16641229]
5. Pisani A, Martella G, Tschertter A, Costa C, Mercuri NB, Bernardi G, Shen J, Calabresi P. Enhanced sensitivity of DJ-1-deficient dopaminergic neurons to energy metabolism impairment: role of Na⁺/K⁺ ATPase. *Neurobiology of disease*. 2006; 23:54–60. [PubMed: 16624565]
6. Pissadaki EK, Bolam JP. The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. *Frontiers in computational neuroscience*. 2013; 7:13. [PubMed: 23515615]
7. Yin LH, Shen H, Diaz-Ruiz O, Backman CM, Bae E, Yu SJ, Wang Y. Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson's disease. *BMC neuroscience*. 2012; 13:120. [PubMed: 23040108]
8. Hang L, Thundiyil J, Lim KL. Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuroprotection. *Annals of the New York Academy of Sciences*. 2015; 1350:37–47. [PubMed: 26121488]
9. Schapira AH. Etiology of Parkinson's disease. *Neurology*. 2006; 66:S10–23. [PubMed: 16717248]
10. Koyano F, Okatsu K, Ishigaki S, Fujioka Y, Kimura M, Sobue G, Tanaka K, Matsuda N. The principal PINK1 and Parkin cellular events triggered in response to dissipation of mitochondrial membrane potential occur in primary neurons. *Genes to cells : devoted to molecular & cellular mechanisms*. 2013; 18:672–681. [PubMed: 23751051]
11. McCoy MK, Cookson MR. Mitochondrial quality control and dynamics in Parkinson's disease. *Antioxidants & redox signaling*. 2012; 16:869–882. [PubMed: 21568830]
12. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. *Lancet*. 1989; 1:1269. [PubMed: 2566813]
13. Trancikova A, Tsika E, Moore DJ. Mitochondrial dysfunction in genetic animal models of Parkinson's disease. *Antioxidants & redox signaling*. 2012; 16:896–919. [PubMed: 21848447]
14. Nicholls DG. Mitochondrial function and dysfunction in the cell: its relevance to aging and aging-related disease. *The international journal of biochemistry & cell biology*. 2002; 34:1372–1381. [PubMed: 12200032]
15. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. *Annual review of pathology*. 2010; 5:297–348.
16. Warburg O. On the origin of cancer cells. *Science*. 1956; 123:309–314. [PubMed: 13298683]
17. Devine MJ, Plun-Favreau H, Wood NW. Parkinson's disease and cancer: two wars, one front. *Nature reviews. Cancer*. 2011; 11:812–823. [PubMed: 22020207]
18. Feng DD, Cai W, Chen X. The associations between Parkinson's disease and cancer: the plot thickens. *Transl Neurodegener*. 2015; 4:20. [PubMed: 26504519]
19. Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. *Neuron*. 2003; 37:735–749. [PubMed: 12628165]
20. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. *Cell*. 1999; 98:859–869. [PubMed: 10499802]
21. Murphy MP. How mitochondria produce reactive oxygen species. *The Biochemical journal*. 2009; 417:1–13. [PubMed: 19061483]
22. Wang X, Su B, Liu W, He X, Gao Y, Castellani RJ, Perry G, Smith MA, Zhu X. DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease. *Aging Cell*. 2011; 10:807–823. [PubMed: 21615675]
23. Van Laar VS, Berman SB. The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease. *Neurobiol Dis*. 2013; 51:43–55. [PubMed: 22668779]

24. Kamp F, Exner N, Lutz AK, Wender N, Hegermann J, Brunner B, Nuscher B, Bartels T, Giese A, Beyer K, Eimer S, Winklhofer KF, Haass C. Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1. *EMBO J*. 2010; 29:3571–3589. [PubMed: 20842103]
25. Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K, Munishkina L, Zhang J, Gardner B, Wakabayashi J, Sesaki H, Cheng Y, Finkbeiner S, Nussbaum RL, Masliah E, Edwards RH. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. *J Biol Chem*. 2011; 286:20710–20726. [PubMed: 21489994]
26. Irrcher I, Aleyasin H, Seifert EL, Hewitt SJ, Chhabra S, Phillips M, Lutz AK, Rousseaux MW, Bevilacqua L, Jahani-Asl A, Callaghan S, MacLaurin JG, Winklhofer KF, Rizzu P, Ripstein P, Kim RH, Chen CX, Fon EA, Slack RS, Harper ME, McBride HM, Mak TW, Park DS. Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. *Hum Mol Genet*. 2010; 19:3734–3746. [PubMed: 20639397]
27. Casarejos MJ, Menendez J, Solano RM, Rodriguez-Navarro JA, Garcia de Yébenes J, Mena MA. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. *Journal of neurochemistry*. 2006; 97:934–946. [PubMed: 16573651]
28. Heeman B, Van den Haute C, Aelvoet SA, Valsecchi F, Rodenburg RJ, Reumers V, Debyser Z, Callewaert G, Koopman WJ, Willems PH, Baekelandt V. Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. *Journal of cell science*. 2011; 124:1115–1125. [PubMed: 21385841]
29. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. *The Journal of cell biology*. 2008; 183:795–803. [PubMed: 19029340]
30. Cui M, Tang X, Christian WV, Yoon Y, Tieu K. Perturbations in mitochondrial dynamics induced by human mutant PINK1 can be rescued by the mitochondrial division inhibitor mdivi-1. *The Journal of biological chemistry*. 2010; 285:11740–11752. [PubMed: 20164189]
31. Wang H, Song P, Du L, Tian W, Yue W, Liu M, Li D, Wang B, Zhu Y, Cao C, Zhou J, Chen Q. Parkin ubiquitinates Drp1 for proteasome-dependent degradation: implication of dysregulated mitochondrial dynamics in Parkinson disease. *The Journal of biological chemistry*. 2011; 286:11649–11658. [PubMed: 21292769]
32. Xiong H, Wang D, Chen L, Choo YS, Ma H, Tang C, Xia K, Jiang W, Ronai Z, Zhuang X, Zhang Z. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. *The Journal of clinical investigation*. 2009; 119:650–660. [PubMed: 19229105]
33. Requejo-Aguilar R, Lopez-Fabuel I, Jimenez-Blasco D, Fernandez E, Almeida A, Bolanos JP. DJ1 represses glycolysis and cell proliferation by transcriptionally up-regulating Pink1. *The Biochemical journal*. 2015; 467:303–310. [PubMed: 25670069]
34. Thomas KJ, McCoy MK, Blackinton J, Beilina A, van der Brug M, Sandebring A, Miller D, Maric D, Cedazo-Minguez A, Cookson MR. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. *Human molecular genetics*. 2011; 20:40–50. [PubMed: 20940149]
35. Andres-Mateos E, Perier C, Zhang L, Blanchard-Fillion B, Greco TM, Thomas B, Ko HS, Sasaki M, Ischiropoulos H, Przedborski S, Dawson TM, Dawson VL. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104:14807–14812. [PubMed: 17766438]
36. Wang X, Yan MH, Fujioka H, Liu J, Wilson-Delfosse A, Chen SG, Perry G, Casadesus G, Zhu X. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. *Hum Mol Genet*. 2012; 21:1931–1944. [PubMed: 22228096]
37. Guardia-Laguarta C, Area-Gomez E, Rub C, Liu Y, Magrane J, Becker D, Voos W, Schon EA, Przedborski S. alpha-Synuclein is localized to mitochondria-associated ER membranes. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014; 34:249–259. [PubMed: 24381286]
38. Ottolini D, Cali T, Negro A, Brini M. The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering. *Human molecular genetics*. 2013; 22:2152–2168. [PubMed: 23418303]

39. Zhang P, Tian B. Metabolic syndrome: an important risk factor for Parkinson's disease. *Oxidative medicine and cellular longevity*. 2014; 2014:729194. [PubMed: 24955210]
40. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. *Brain : a journal of neurology*. 2013; 136:374–384. [PubMed: 22344583]
41. Jain D, Jain R, Eberhard D, Eglinger J, Bugliani M, Piemonti L, Marchetti P, Lammert E. Age- and diet-dependent requirement of DJ-1 for glucose homeostasis in mice with implications for human type 2 diabetes. *Journal of molecular cell biology*. 2012; 4:221–230. [PubMed: 22611253]
42. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. *Nature*. 1997; 388:839–840. [PubMed: 9278044]
43. Scheuner D, Kaufman RJ. The unfolded protein response: a pathway that links insulin demand with beta-cell failure and diabetes. *Endocrine reviews*. 2008; 29:317–333. [PubMed: 18436705]
44. Wang L, Zhai YQ, Xu LL, Qiao C, Sun XL, Ding JH, Lu M, Hu G. Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. *Experimental neurology*. 2014; 251:22–29. [PubMed: 24220636]
45. Ferrari CC, Tarelli R. Parkinson's disease and systemic inflammation. *Parkinson's disease*. 2011; 2011:436813.
46. Boni-Schnetzler M, Thorne J, Parnaud G, Marselli L, Ehses JA, Kerr-Conte J, Pattou F, Halban PA, Weir GC, Donath MY. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. *The Journal of clinical endocrinology and metabolism*. 2008; 93:4065–4074. [PubMed: 18664535]
47. Takahashi M, Yamada T, Tooyama I, Moroo I, Kimura H, Yamamoto T, Okada H. Insulin receptor mRNA in the substantia nigra in Parkinson's disease. *Neuroscience letters*. 1996; 204:201–204. [PubMed: 8938265]
48. Levin BE. Glucose-regulated dopamine release from substantia nigra neurons. *Brain research*. 2000; 874:158–164. [PubMed: 10960600]
49. Morris JK, Bomhoff GL, Stanford JA, Geiger PC. Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. *American journal of physiology. Regulatory, integrative and comparative physiology*. 2010; 299:R1082–1090.
50. Lyn-Cook LE Jr, Lawton M, Tong M, Silbermann E, Longato L, Jiao P, Mark P, Wands JR, Xu H, de la Monte SM. Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. *Journal of Alzheimer's disease : JAD*. 2009; 16:715–729. [PubMed: 19387108]
51. Tanner CM. Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look. *Neurology*. 1991; 41:89–91. discussion 92. [PubMed: 2041601]
52. Wojcikowski J, Daniel WA. The brain dopaminergic system as an important center regulating liver cytochrome P450 in the rat. *Expert opinion on drug metabolism & toxicology*. 2009; 5:631–645. [PubMed: 19442036]
53. Pacelli C, Giguere N, Bourque MJ, Levesque M, Slack RS, Trudeau LE. Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons. *Current biology : CB*. 2015; 25:2349–2360. [PubMed: 26320949]
54. Benskey M, Behrouz B, Sunryd J, Pappas SS, Baek SH, Huebner M, Lookingland KJ, Goudreau JL. Recovery of hypothalamic tuberoinfundibular dopamine neurons from acute toxicant exposure is dependent upon protein synthesis and associated with an increase in parkin and ubiquitin carboxy-terminal hydrolase-L1 expression. *Neurotoxicology*. 2012; 33:321–331. [PubMed: 22342763]
55. Chinta SJ, Andersen JK. Redox imbalance in Parkinson's disease. *Biochimica et biophysica acta*. 2008; 1780:1362–1367. [PubMed: 18358848]
56. Davey GP, Bolanos JP. Peroxiredoxin 5 links mitochondrial redox signalling with calcium dynamics: impact on Parkinson's disease. *Journal of neurochemistry*. 2013; 125:332–333. [PubMed: 23442153]
57. Kish SJ, Morito C, Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. *Neuroscience letters*. 1985; 58:343–346. [PubMed: 4047494]

58. Chan CS, Gertler TS, Surmeier DJ. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society*. 2010; 25(Suppl 1):S63–70. [PubMed: 20187241]
59. Guzman JN, Sanchez-Padilla J, Chan CS, Surmeier DJ. Robust pacemaking in substantia nigra dopaminergic neurons. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2009; 29:11011–11019. [PubMed: 19726659]
60. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA. The origins of oxidant stress in Parkinson's disease and therapeutic strategies. *Antioxidants & redox signaling*. 2011; 14:1289–1301. [PubMed: 20712409]
61. Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. *The Lancet. Neurology*. 2007; 6:933–938. [PubMed: 17884683]
62. Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. *Neurobiology of disease*. 2011; 43:364–371. [PubMed: 21515375]
63. Xie B, Lin F, Ullah K, Peng L, Ding W, Dai R, Qing H, Deng Y. A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson's disease. *Biochemical and biophysical research communications*. 2015; 459:361–366. [PubMed: 25744031]
64. Yan MH, Wang X, Zhu X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. *Free radical biology & medicine*. 2013; 62:90–101. [PubMed: 23200807]
65. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. *Neurology*. 2006; 66:S24–36. [PubMed: 16717250]
66. McNaught KS, Jenner P. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. *Journal of neurochemistry*. 1999; 73:2469–2476. [PubMed: 10582607]
67. Munoz P, Huenchuguala S, Paris I, Segura-Aguilar J. Dopamine oxidation and autophagy. *Parkinson's disease*. 2012; 2012:920953.
68. Jenner P, Langston JW. Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. *Movement disorders : official journal of the Movement Disorder Society*. 2011; 26:2316–2323. [PubMed: 21953831]
69. Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. *Toxicology*. 2011; 283:65–87. [PubMed: 21414382]
70. Nunez MT, Urrutia P, Mena N, Aguirre P, Tapia V, Salazar J. Iron toxicity in neurodegeneration. *Biomaterials : an international journal on the role of metal ions in biology, biochemistry, and medicine*. 2012; 25:761–776.
71. Sziraki I, Mohanakumar KP, Rauhala P, Kim HG, Yeh KJ, Chiueh CC. Manganese: a transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism. *Neuroscience*. 1998; 85:1101–1111. [PubMed: 9681949]
72. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. *Neuroscience*. 2011; 198:221–231. [PubMed: 21884755]
73. Doorn KJ, Moors T, Drukarch B, van de Berg W, Lucassen PJ, van Dam AM. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients. *Acta neuropathologica communications*. 2014; 2:90. [PubMed: 25099483]
74. Herrera AJ, Castano A, Venero JL, Cano J, Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. *Neurobiology of disease*. 2000; 7:429–447. [PubMed: 10964613]
75. Iravani MM, Sadeghian M, Leung CC, Jenner P, Rose S. Lipopolysaccharide-induced nigral inflammation leads to increased IL-1beta tissue content and expression of astrocytic glial cell line-derived neurotrophic factor. *Neuroscience letters*. 2012; 510:138–142. [PubMed: 22281445]
76. Barcia C, Ros CM, Carrillo MA, Ros F, Gomez A, de Pablos V, Bautista-Hernandez V, Sanchez-Bahillo A, Villalba EF, Herrero MT. Increase of secondary processes of microglial and astroglial

- cells after MPTP-induced degeneration in substantia nigra pars compacta of non human primates. *Journal of neural transmission. Supplementum*. 2009;253–258. [PubMed: 20411783]
77. Emmrich JV, Hornik TC, Neher JJ, Brown GC. Rotenone induces neuronal death by microglial phagocytosis of neurons. *The FEBS journal*. 2013; 280:5030–5038. [PubMed: 23789887]
78. Wilhelmus MM, Nijland PG, Drukarch B, de Vries HE, van Horssen J. Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders. *Free radical biology & medicine*. 2012; 53:983–992. [PubMed: 22687462]
79. Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress and Parkinson's disease. *Frontiers in neuroanatomy*. 2015; 9:91. [PubMed: 26217195]
80. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. *The Lancet. Neurology*. 2008; 7:97–109. [PubMed: 18093566]
81. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. *Journal of neurochemistry*. 1990; 54:823–827. [PubMed: 2154550]
82. Hattori N, Tanaka M, Ozawa T, Mizuno Y. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. *Annals of neurology*. 1991; 30:563–571. [PubMed: 1665052]
83. Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, Zanella F, Hilker R. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. *Brain : a journal of neurology*. 2009; 132:3285–3297. [PubMed: 19952056]
84. Hasegawa E, Takeshige K, Oishi T, Murai Y, Minakami S. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. *Biochemical and biophysical research communications*. 1990; 170:1049–1055. [PubMed: 2167668]
85. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. Mechanism of toxicity in rotenone models of Parkinson's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2003; 23:10756–10764. [PubMed: 14645467]
86. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. *The Journal of biological chemistry*. 2004; 279:18614–18622. [PubMed: 14985362]
87. Requejo-Aguilar R, Lopez-Fabuel I, Fernandez E, Martins LM, Almeida A, Bolanos JP. PINK1 deficiency sustains cell proliferation by reprogramming glucose metabolism through HIF1. *Nature communications*. 2014; 5:4514.
88. Heo JY, Park JH, Kim SJ, Seo KS, Han JS, Lee SH, Kim JM, Park JI, Park SK, Lim K, Hwang BD, Shong M, Kweon GR. DJ-1 null dopaminergic neuronal cells exhibit defects in mitochondrial function and structure: involvement of mitochondrial complex I assembly. *PloS one*. 2012; 7:e32629. [PubMed: 22403686]
89. Wen Y, Li W, Poteet EC, Xie L, Tan C, Yan LJ, Ju X, Liu R, Qian H, Marvin MA, Goldberg MS, She H, Mao Z, Simpkins JW, Yang SH. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. *The Journal of biological chemistry*. 2011; 286:16504–16515. [PubMed: 21454572]
90. Wu SB, Wei YH. AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: implication of the cell survival in mitochondrial diseases. *Biochimica et biophysica acta*. 2012; 1822:233–247. [PubMed: 22001850]
91. Higaki Y, Mikami T, Fujii N, Hirshman MF, Koyama K, Seino T, Tanaka K, Goodyear LJ. Oxidative stress stimulates skeletal muscle glucose uptake through a phosphatidylinositol 3-kinase-dependent pathway. *American journal of physiology. Endocrinology and metabolism*. 2008; 294:E889–897. [PubMed: 18303121]
92. Jensen TE, Schjerling P, Viollet B, Wojtaszewski JF, Richter EA. AMPK alpha1 activation is required for stimulation of glucose uptake by twitch contraction, but not by H2O2, in mouse skeletal muscle. *PloS one*. 2008; 3:e2102. [PubMed: 18461163]

93. Kim JS, Saengsirisuwan V, Sloniger JA, Teachey MK, Henriksen EJ. Oxidant stress and skeletal muscle glucose transport: roles of insulin signaling and p38 MAPK. *Free radical biology & medicine*. 2006; 41:818–824. [PubMed: 16895802]
94. Prasad RK, Ismail-Beigi F. Mechanism of stimulation of glucose transport by H₂O₂: role of phospholipase C. *Archives of biochemistry and biophysics*. 1999; 362:113–122. [PubMed: 9917335]
95. Andrisse S, Koehler RM, Chen JE, Patel GD, Vallurupalli VR, Ratliff BA, Warren DE, Fisher JS. Role of GLUT1 in regulation of reactive oxygen species. *Redox biology*. 2014; 2:764–771. [PubMed: 25101238]
96. Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. *Molecular aspects of medicine*. 2013; 34:121–138. [PubMed: 23506862]
97. Kozlovsky N, Rudich A, Potashnik R, Ebina Y, Murakami T, Bashan N. Transcriptional activation of the Glut1 gene in response to oxidative stress in L6 myotubes. *The Journal of biological chemistry*. 1997; 272:33367–33372. [PubMed: 9407130]
98. Ebert BL, Firth JD, Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. *The Journal of biological chemistry*. 1995; 270:29083–29089. [PubMed: 7493931]
99. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT, Simon MC. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF- α activation. *Cell metabolism*. 2005; 1:393–399. [PubMed: 16054088]
100. Fryer LG, Foulfelle F, Barnes K, Baldwin SA, Woods A, Carling D. Characterization of the role of the AMP-activated protein kinase in the stimulation of glucose transport in skeletal muscle cells. *The Biochemical journal*. 2002; 363:167–174. [PubMed: 11903059]
101. Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, Fogarty S, Towler MC, Brown LJ, Ogunbayo OA, Evans AM, Hardie DG. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. *Cell metabolism*. 2010; 11:554–565. [PubMed: 20519126]
102. Emerling BM, Weinberg F, Snyder C, Burgess Z, Mutlu GM, Viollet B, Budinger GR, Chandel NS. Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. *Free radical biology & medicine*. 2009; 46:1386–1391. [PubMed: 19268526]
103. Ciudad P, Almeida A, Bolanos JP. Inhibition of mitochondrial respiration by nitric oxide rapidly stimulates cytoprotective GLUT3-mediated glucose uptake through 5'-AMP-activated protein kinase. *The Biochemical journal*. 2004; 384:629–636. [PubMed: 15320870]
104. Liu YJ, Chern Y. AMPK-mediated regulation of neuronal metabolism and function in brain diseases. *Journal of neurogenetics*. 2015; 29:50–58. [PubMed: 26119401]
105. Andrisse S, Patel GD, Chen JE, Webber AM, Spears LD, Koehler RM, Robinson-Hill RM, Ching JK, Jeong I, Fisher JS. ATM and GLUT1-S490 phosphorylation regulate GLUT1 mediated transport in skeletal muscle. *PloS one*. 2013; 8:e66027. [PubMed: 23776597]
106. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. *Science*. 2010; 330:517–521. [PubMed: 20966255]
107. Morita A, Tanimoto K, Murakami T, Morinaga T, Hosoi Y. Mitochondria are required for ATM activation by extranuclear oxidative stress in cultured human hepatoblastoma cell line Hep G2 cells. *Biochem Biophys Res Commun*. 2014; 443:1286–1290. [PubMed: 24406161]
108. Le Goffe C, Vallette G, Charrier L, Candelon T, Bou-Hanna C, Bouhours JF, Laboisie CL. Metabolic control of resistance of human epithelial cells to H₂O₂ and NO stresses. *The Biochemical journal*. 2002; 364:349–359. [PubMed: 12023877]
109. Herrero-Mendez A, Almeida A, Fernandez E, Maestre C, Moncada S, Bolanos JP. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. *Nature cell biology*. 2009; 11:747–752. [PubMed: 19448625]
110. Rodriguez-Rodriguez P, Fernandez E, Almeida A, Bolanos JP. Excitotoxic stimulus stabilizes PFKFB3 causing pentose-phosphate pathway to glycolysis switch and neurodegeneration. *Cell Death Differ*. 2012; 19:1582–1589. [PubMed: 22421967]

111. Dunn L, Allen GF, Mamais A, Ling H, Li A, Duberley KE, Hargreaves IP, Pope S, Holton JL, Lees A, Heales SJ, Bandopadhyay R. Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease. *Neurobiology of aging*. 2014; 35:1111–1115. [PubMed: 24300239]
112. Bouzier-Sore AK, Bolanos JP. Uncertainties in pentose-phosphate pathway flux assessment underestimate its contribution to neuronal glucose consumption: relevance for neurodegeneration and aging. *Front Aging Neurosci*. 2015; 7:89. [PubMed: 26042035]
113. Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, Waddington SN, Schapira AH, Duchen MR. Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson's disease. *Cell metabolism*. 2013; 17:941–953. [PubMed: 23707074]
114. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. *Nature reviews. Drug discovery*. 2007; 6:304–312. [PubMed: 17396135]
115. Martinez-Vicente M, Cuervo AM. Autophagy and neurodegeneration: when the cleaning crew goes on strike. *The Lancet. Neurology*. 2007; 6:352–361. [PubMed: 17362839]
116. Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. *Brain : a journal of neurology*. 2008; 131:1969–1978. [PubMed: 18187492]
117. Cesen MH, Pegan K, Spes A, Turk B. Lysosomal pathways to cell death and their therapeutic applications. *Experimental cell research*. 2012; 318:1245–1251. [PubMed: 22465226]
118. Churchill GC, Okada Y, Thomas JM, Genazzani AA, Patel S, Galione A. NAADP mobilizes Ca(2+) from reserve granules, lysosome-related organelles, in sea urchin eggs. *Cell*. 2002; 111:703–708. [PubMed: 12464181]
119. Kilpatrick BS, Eden ER, Schapira AH, Futter CE, Patel S. Direct mobilisation of lysosomal Ca2+ triggers complex Ca2+ signals. *Journal of cell science*. 2013; 126:60–66. [PubMed: 23108667]
120. Chieriegatti E, Meldolesi J. Regulated exocytosis: new organelles for non-secretory purposes. *Nature reviews. Molecular cell biology*. 2005; 6:181–187. [PubMed: 15688003]
121. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. *Cell*. 2010; 141:290–303. [PubMed: 20381137]
122. Osellame LD, Duchen MR. Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration. *British journal of pharmacology*. 2014; 171:1958–1972. [PubMed: 24116849]
123. Zheng J, Yan T, Feng Y, Zhai Q. Involvement of lysosomes in the early stages of axon degeneration. *Neurochemistry international*. 2010; 56:516–521. [PubMed: 20036294]
124. Settembre C, Fraldi A, Rubinsztein DC, Ballabio A. Lysosomal storage diseases as disorders of autophagy. *Autophagy*. 2008; 4:113–114. [PubMed: 18000397]
125. Rusinol AE, Cui Z, Chen MH, Vance JE. A unique mitochondria-associated membrane fraction from rat liver has a high capacity for lipid synthesis and contains pre-Golgi secretory proteins including nascent lipoproteins. *The Journal of biological chemistry*. 1994; 269:27494–27502. [PubMed: 7961664]
126. Rizzuto R, Pinton P, Carrington W, Fay FS, Fogarty KE, Lifshitz LM, Tuft RA, Pozzan T. Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. *Science*. 1998; 280:1763–1766. [PubMed: 9624056]
127. Vance JE. Phospholipid synthesis in a membrane fraction associated with mitochondria. *The Journal of biological chemistry*. 1990; 265:7248–7256. [PubMed: 2332429]
128. Bravo-Sagua R, Torrealba N, Paredes F, Morales PE, Pennanen C, Lopez-Crisosto C, Troncoso R, Criollo A, Chiong M, Hill JA, Simmen T, Quest AF, Lavandero S. Organelle communication: signaling crossroads between homeostasis and disease. *The international journal of biochemistry & cell biology*. 2014; 50:55–59. [PubMed: 24534274]
129. Marchi S, Patergnani S, Pinton P. The endoplasmic reticulum-mitochondria connection: one touch, multiple functions. *Biochimica et biophysica acta*. 2014; 1837:461–469. [PubMed: 24211533]
130. McCormack JG, Halestrap AP, Denton RM. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. *Physiological reviews*. 1990; 70:391–425. [PubMed: 2157230]

131. Mammucari C, Patron M, Granatiero V, Rizzuto R. Molecules and roles of mitochondrial calcium signaling. *BioFactors*. 2011; 37:219–227. [PubMed: 21674643]
132. Cali T, Ottolini D, Brini M. Mitochondrial Ca(2+) as a key regulator of mitochondrial activities. *Advances in experimental medicine and biology*. 2012; 942:53–73. [PubMed: 22399418]
133. Brustovetsky N, Dubinsky JM, Antonsson B, Jemmerson R. Two pathways for tBID-induced cytochrome c release from rat brain mitochondria: BAK- versus BAX-dependence. *Journal of neurochemistry*. 2003; 84:196–207. [PubMed: 12485416]
134. Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, Korsmeyer SJ. BAX and BAK regulation of endoplasmic reticulum Ca²⁺: a control point for apoptosis. *Science*. 2003; 300:135–139. [PubMed: 12624178]
135. Bravo R, Gutierrez T, Paredes F, Gatica D, Rodriguez AE, Pedrozo Z, Chiong M, Parra V, Quest AF, Rothermel BA, Lavandero S. Endoplasmic reticulum: ER stress regulates mitochondrial bioenergetics. *The international journal of biochemistry & cell biology*. 2012; 44:16–20. [PubMed: 22064245]
136. Bravo R, Vicencio JM, Parra V, Troncoso R, Munoz JP, Bui M, Quiroga C, Rodriguez AE, Verdejo HE, Ferreira J, Iglewski M, Chiong M, Simmen T, Zorzano A, Hill JA, Rothermel BA, Szabadkai G, Lavandero S. Increased ER-mitochondrial coupling promotes mitochondrial respiration and bioenergetics during early phases of ER stress. *Journal of cell science*. 2011; 124:2143–2152. [PubMed: 21628424]
137. Tubbs E, Theurey P, Vial G, Bendridi N, Bravard A, Chauvin MA, Ji-Cao J, Zoulim F, Bartosch B, Ovize M, Vidal H, Rieusset J. Mitochondria-associated endoplasmic reticulum membrane (MAM) integrity is required for insulin signaling and is implicated in hepatic insulin resistance. *Diabetes*. 2014; 63:3279–3294. [PubMed: 24947355]
138. Betz C, Stracka D, Prescianotto-Baschong C, Frieden M, Demaurex N, Hall MN. Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. *Proceedings of the National Academy of Sciences of the United States of America*. 2013; 110:12526–12534. [PubMed: 23852728]
139. Giorgi C, Ito K, Lin HK, Santangelo C, Wieckowski MR, Lebiedzinska M, Bononi A, Bonora M, Duszynski J, Bernardi R, Rizzuto R, Tacchetti C, Pinton P, Pandolfi PP. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. *Science*. 2010; 330:1247–1251. [PubMed: 21030605]
140. del Campo A, Parra V, Vasquez-Trincado C, Gutierrez T, Morales PE, Lopez-Crisosto C, Bravo-Sagua R, Navarro-Marquez MF, Verdejo HE, Contreras-Ferrat A, Troncoso R, Chiong M, Lavandero S. Mitochondrial fragmentation impairs insulin-dependent glucose uptake by modulating Akt activity through mitochondrial Ca²⁺ uptake. *American journal of physiology. Endocrinology and metabolism*. 2014; 306:E1–E13. [PubMed: 24085037]
141. Gutierrez T, Parra V, Troncoso R, Pennanen C, Contreras-Ferrat A, Vasquez-Trincado C, Morales PE, Lopez-Crisosto C, Sotomayor-Flores C, Chiong M, Rothermel BA, Lavandero S. Alteration in mitochondrial Ca(2+) uptake disrupts insulin signaling in hypertrophic cardiomyocytes. *Cell communication and signaling : CCS*. 2014; 12:68. [PubMed: 25376904]
142. Arruda AP, Pers BM, Parlakgul G, Guney E, Inouye K, Hotamisligil GS. Chronic enrichment of hepatic endoplasmic reticulum-mitochondria contact leads to mitochondrial dysfunction in obesity. *Nature medicine*. 2014; 20:1427–1435.
143. Parker WD Jr, Parks JK, Swerdlow RH. Complex I deficiency in Parkinson's disease frontal cortex. *Brain research*. 2008; 1189:215–218. [PubMed: 18061150]
144. Mytilineou C, Werner P, Molinari S, Di Rocco A, Cohen G, Yahr MD. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease. *Journal of neural transmission. Parkinson's disease and dementia section*. 1994; 8:223–228.
145. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AH. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. *Annals of neurology*. 1992; 32:782–788. [PubMed: 1471869]
146. Blin O, Desnuelle C, Rascol O, Borg M, Peyro Saint Paul H, Azulay JP, Bille F, Figarella D, Couloul F, Pellissier JF, et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. *Journal of the neurological sciences*. 1994; 125:95–101. [PubMed: 7964895]

147. Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, Shults CW. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. *Annals of neurology*. 1995; 37:714–722. [PubMed: 7778844]
148. Martinez TN, Greenamyre JT. Toxin models of mitochondrial dysfunction in Parkinson's disease. *Antioxidants & redox signaling*. 2012; 16:920–934. [PubMed: 21554057]
149. Simola N, Morelli M, Carta AR. The 6-hydroxydopamine model of Parkinson's disease. *Neurotoxicity research*. 2007; 11:151–167. [PubMed: 17449457]
150. Adams JD Jr, Odunze IN. Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Could oxidative stress be involved in the brain? *Biochemical pharmacology*. 1991; 41:1099–1105. [PubMed: 2009088]
151. Przedborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. *Movement disorders : official journal of the Movement Disorder Society*. 1998; 13(Suppl 1):35–38.
152. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. *Proceedings of the National Academy of Sciences of the United States of America*. 1985; 82:2173–2177. [PubMed: 3872460]
153. Ramsay RR, Singer TP. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. *The Journal of biological chemistry*. 1986; 261:7585–7587. [PubMed: 3486869]
154. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. *Journal of neurochemistry*. 1993; 61:1191–1206. [PubMed: 8376979]
155. Bates TE, Heales SJ, Davies SE, Boakye P, Clark JB. Effects of 1-methyl-4-phenylpyridinium on isolated rat brain mitochondria: evidence for a primary involvement of energy depletion. *Journal of neurochemistry*. 1994; 63:640–648. [PubMed: 8035188]
156. Mazzio E, Soliman KF. The role of glycolysis and gluconeogenesis in the cytoprotection of neuroblastoma cells against 1-methyl-4-phenylpyridinium ion toxicity. *Neurotoxicology*. 2003; 24:137–147. [PubMed: 12564389]
157. Chalmers-Redman RM, Fraser AD, Carlile GW, Pong A, Tatton WG. Glucose protection from MPP+-induced apoptosis depends on mitochondrial membrane potential and ATP synthase. *Biochemical and biophysical research communications*. 1999; 257:440–447. [PubMed: 10198232]
158. Wu EY, Langston JW, Di Monte DA. Toxicity of the 1-methyl-4-phenyl-2,3-dihydropyridinium and 1-methyl-4-phenylpyridinium species in primary cultures of mouse astrocytes. *The Journal of pharmacology and experimental therapeutics*. 1992; 262:225–230. [PubMed: 1625201]
159. Mazzio E, Soliman KF. D-(+)-glucose rescue against 1-methyl-4-phenylpyridinium toxicity through anaerobic glycolysis in neuroblastoma cells. *Brain research*. 2003; 962:48–60. [PubMed: 12543455]
160. Maruoka N, Murata T, Omata N, Takashima Y, Fujibayashi Y, Wada Y. Biphasic mechanism of the toxicity induced by 1-methyl-4-phenylpyridinium ion (MPP+) as revealed by dynamic changes in glucose metabolism in rat brain slices. *Neurotoxicology*. 2007; 28:672–678. [PubMed: 17391768]
161. Chaudhuri AD, Kabaria S, Choi DC, Mouradian MM, Junn E. MicroRNA-7 Promotes Glycolysis to Protect against 1-Methyl-4-phenylpyridinium-induced Cell Death. *The Journal of biological chemistry*. 2015; 290:12425–12434. [PubMed: 25814668]
162. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW. Rotenone, paraquat, and Parkinson's disease. *Environmental health perspectives*. 2011; 119:866–872. [PubMed: 21269927]
163. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. *Nature neuroscience*. 2000; 3:1301–1306. [PubMed: 11100151]
164. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-

synuclein metabolism and oxidative damage. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2002; 22:7006–7015. [PubMed: 12177198]

165. Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Experimental neurology. 2003; 179:9–16. [PubMed: 12504863]
166. Borland MK, Trimmer PA, Rubinstein JD, Keeney PM, Mohanakumar K, Liu L, Bennett JP Jr. Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Molecular neurodegeneration. 2008; 3:21. [PubMed: 19114014]
167. Giordano S, Lee J, Darley-Usmar VM, Zhang J. Distinct effects of rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on cellular bioenergetics and cell death. PloS one. 2012; 7:e44610. [PubMed: 22970265]
168. Radad K, Rausch WD, Gille G. Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochemistry international. 2006; 49:379–386. [PubMed: 16580092]
169. Huang J, Hao L, Xiong N, Cao X, Liang Z, Sun S, Wang T. Involvement of glyceraldehyde-3-phosphate dehydrogenase in rotenone-induced cell apoptosis: relevance to protein misfolding and aggregation. Brain research. 2009; 1279:1–8. [PubMed: 19445904]
170. Curtius HC, Wolfensberger M, Steinmann B, Redweik U, Siegfried J. Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. Journal of chromatography. 1974; 99:529–540. [PubMed: 4153550]
171. Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, Petty RK. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochemical research. 1993; 18:1175–1177. [PubMed: 8255370]
172. Glinka YY, Youdim MB. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. European journal of pharmacology. 1995; 292:329–332. [PubMed: 7796873]
173. Cohen G, Heikkila RE. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. The Journal of biological chemistry. 1974; 249:2447–2452. [PubMed: 4362682]
174. Jameson GN, Jameson RF, Linert W. New insights into iron release from ferritin: direct observation of the neurotoxin 6-hydroxydopamine entering ferritin and reaching redox equilibrium with the iron core. Organic & biomolecular chemistry. 2004; 2:2346–2351. [PubMed: 15305217]
175. Fasano M, Bergamasco B, Lopiano L. Modifications of the iron-neuromelanin system in Parkinson's disease. Journal of neurochemistry. 2006; 96:909–916. [PubMed: 16417570]
176. Sian-Hulsmann J, Mandel S, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Journal of neurochemistry. 2011; 118:939–957. [PubMed: 21138437]
177. Lei S, Zavala-Flores L, Garcia-Garcia A, Nandakumar R, Huang Y, Madayiputhiya N, Stanton RC, Dodds ED, Powers R, Franco R. Alterations in energy/redox metabolism induced by mitochondrial and environmental toxins: a specific role for glucose-6-phosphate-dehydrogenase and the pentose phosphate pathway in paraquat toxicity. ACS chemical biology. 2014; 9:2032–2048. [PubMed: 24937102]
178. Wu B, Song B, Yang H, Huang B, Chi B, Guo Y, Liu H. Central nervous system damage due to acute paraquat poisoning: an experimental study with rat model. Neurotoxicology. 2013; 35:62–70. [PubMed: 23261591]
179. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiology of disease. 2002; 10:119–127. [PubMed: 12127150]
180. Ossowska K, Wardas J, Smialowska M, Kuter K, Lenda T, Wieronska JM, Zieba B, Nowak P, Dabrowska J, Bortel A, Kwiecinski A, Wolfarth S. A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an

animal model of preclinical stages of Parkinson's disease? The European journal of neuroscience. 2005; 22:1294–1304. [PubMed: 16190885]

181. Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicological sciences : an official journal of the Society of Toxicology. 2005; 88:193–201. [PubMed: 16141438]
182. Yumino K, Kawakami I, Tamura M, Hayashi T, Nakamura M. Paraquat- and diquat-induced oxygen radical generation and lipid peroxidation in rat brain microsomes. Journal of biochemistry. 2002; 131:565–570. [PubMed: 11926994]
183. Thiruchelvam M, Prokopenko O, Cory-Slechta DA, Buckley B, Mirochnitchenko O. Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat + maneb-induced Parkinson disease phenotype. The Journal of biological chemistry. 2005; 280:22530–22539. [PubMed: 15824117]
184. Shimizu K, Matsubara K, Ohtaki K, Fujimaru S, Saito O, Shiono H. Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats. Brain research. 2003; 976:243–252. [PubMed: 12763259]
185. Gasser T. Mendelian forms of Parkinson's disease. Biochimica et biophysica acta. 2009; 1792:587–596. [PubMed: 19168133]
186. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annual review of neuroscience. 2005; 28:57–87.
187. Thomas B, Beal MF. Parkinson's disease. Human molecular genetics. 2007; 16(Spec No. 2):R183–194. [PubMed: 17911161]
188. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276:2045–2047. [PubMed: 9197268]
189. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature genetics. 1998; 18:106–108. [PubMed: 9462735]
190. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muentner M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003; 302:841. [PubMed: 14593171]
191. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Ates B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Annals of neurology. 2004; 55:164–173. [PubMed: 14755719]
192. Butler EK, Voigt A, Lutz AK, Toegel JP, Gerhardt E, Karsten P, Falkenburger B, Reinartz A, Winklhofer KF, Schulz JB. The mitochondrial chaperone protein TRAP1 mitigates alpha-Synuclein toxicity. PLoS genetics. 2012; 8:e1002488. [PubMed: 22319455]
193. Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease. Neurobiology of disease. 2005; 18:492–498. [PubMed: 15755676]
194. Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cellular and molecular life sciences : CMLS. 2008; 65:1272–1284. [PubMed: 18322646]
195. Chu Y, Kordower JH. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiology of disease. 2007; 25:134–149. [PubMed: 17055279]
196. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, Okochi M, Leimer U, van Der Putten H, Probst A, Kremmer E, Kretschmar HA, Haass C. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha - synuclein in human and transgenic mouse brain. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2000; 20:6365–6373. [PubMed: 10964942]

197. Gorbatyuk MS, Shabashvili A, Chen W, Meyers C, Sullivan LF, Salganik M, Lin JH, Lewin AS, Muzyczka N, Gorbatyuk OS. Glucose regulated protein 78 diminishes alpha-synuclein neurotoxicity in a rat model of Parkinson disease. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2012; 20:1327–1337. [PubMed: 22434142]
198. Csordas G, Varnai P, Golenar T, Roy S, Purkins G, Schneider TG, Balla T, Hajnoczky G. Imaging interorganelle contacts and local calcium dynamics at the ER-mitochondrial interface. *Molecular cell*. 2010; 39:121–132. [PubMed: 20603080]
199. Rothman SM, Griffioen KJ, Fishbein KW, Spencer RG, Makrogiannis S, Cong WN, Martin B, Mattson MP. Metabolic abnormalities and hypoleptinemia in alpha-synuclein A53T mutant mice. *Neurobiology of aging*. 2014; 35:1153–1161. [PubMed: 24239384]
200. Geng X, Lou H, Wang J, Li L, Swanson AL, Sun M, Beers-Stolz D, Watkins S, Perez RG, Drain P. alpha-Synuclein binds the K(ATP) channel at insulin-secreting granules and inhibits insulin secretion. *American journal of physiology. Endocrinology and metabolism*. 2011; 300:E276–286. [PubMed: 20858756]
201. Rodriguez-Araujo G, Nakagami H, Takami Y, Katsuya T, Akasaka H, Saitoh S, Shimamoto K, Morishita R, Rakugi H, Kaneda Y. Low alpha-synuclein levels in the blood are associated with insulin resistance. *Scientific reports*. 2015; 5:12081. [PubMed: 26159928]
202. Rodriguez-Araujo G, Nakagami H, Hayashi H, Mori M, Shiuchi T, Minokoshi Y, Nakaoka Y, Takami Y, Komuro I, Morishita R, Kaneda Y. Alpha-synuclein elicits glucose uptake and utilization in adipocytes through the Gab1/PI3K/Akt transduction pathway. *Cellular and molecular life sciences : CMLS*. 2013; 70:1123–1133. [PubMed: 23124190]
203. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature*. 1998; 392:605–608. [PubMed: 9560156]
204. Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, De Michele G, Bouley S, Vaughan JR, Gasser T, Marconi R, Broussolle E, Brefel-Courbon C, Harhangi BS, Oostra BA, Fabrizio E, Bohme GA, Pradier L, Wood NW, Filla A, Meco G, Deneffe P, Agid Y, Brice A. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. *Human molecular genetics*. 1999; 8:567–574. [PubMed: 10072423]
205. Dawson TM. Parkin and defective ubiquitination in Parkinson's disease. *Journal of neural transmission. Supplementum*. 2006:209–213. [PubMed: 17017531]
206. Kuroda Y, Mitsui T, Kunishige M, Shono M, Akaike M, Azuma H, Matsumoto T. Parkin enhances mitochondrial biogenesis in proliferating cells. *Human molecular genetics*. 2006; 15:883–895. [PubMed: 16449237]
207. Darios F, Corti O, Lucking CB, Hampe C, Muriel MP, Abbas N, Gu WJ, Hirsch EC, Rooney T, Ruberg M, Brice A. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. *Human molecular genetics*. 2003; 12:517–526. [PubMed: 12588799]
208. Bian M, Liu J, Hong X, Yu M, Huang Y, Sheng Z, Fei J, Huang F. Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. *PloS one*. 2012; 7:e39953. [PubMed: 22792139]
209. Muftuoglu M, Elibol B, Dalmizrak O, Ercan A, Kulaksiz G, Ogus H, Dalkara T, Ozer N. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. *Movement disorders : official journal of the Movement Disorder Society*. 2004; 19:544–548. [PubMed: 15133818]
210. Rosen KM, Veereshwarayya V, Moussa CE, Fu Q, Goldberg MS, Schlossmacher MG, Shen J, Querfurth HW. Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells. *The Journal of biological chemistry*. 2006; 281:12809–12816. [PubMed: 16517603]
211. Sonia Angeline M, Chaterjee P, Anand K, Ambasta RK, Kumar P. Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat. *Neuroscience*. 2012; 220:291–301. [PubMed: 22710069]

212. Sun Y, Vashisht AA, Tchieu J, Wohlschlegel JA, Dreier L. Voltage-dependent anion channels (VDACs) recruit Parkin to defective mitochondria to promote mitochondrial autophagy. *The Journal of biological chemistry*. 2012; 287:40652–40660. [PubMed: 23060438]
213. Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, Rice S, Steen J, LaVoie MJ, Schwarz TL. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. *Cell*. 2011; 147:893–906. [PubMed: 22078885]
214. Yu W, Sun Y, Guo S, Lu B. The PINK1/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons. *Human molecular genetics*. 2011; 20:3227–3240. [PubMed: 21613270]
215. Cook KL, Soto-Pantoja DR, Abu-Asab M, Clarke PA, Roberts DD, Clarke R. Mitochondria directly donate their membrane to form autophagosomes during a novel mechanism of parkin-associated mitophagy. *Cell Biosci*. 2014; 4:16. [PubMed: 24669863]
216. Bouman L, Schlierf A, Lutz AK, Shan J, Deinlein A, Kast J, Galehdar Z, Palmisano V, Patenge N, Berg D, Gasser T, Augustin R, Trumbach D, Irrcher I, Park DS, Wurst W, Kilberg MS, Tatzelt J, Winklhofer KF. Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. *Cell death and differentiation*. 2011; 18:769–782. [PubMed: 21113145]
217. Cali T, Ottolini D, Negro A, Brini M. Enhanced parkin levels favor ER-mitochondria crosstalk and guarantee Ca(2+) transfer to sustain cell bioenergetics. *Biochimica et biophysica acta*. 2013; 1832:495–508. [PubMed: 23313576]
218. Kim KY, Stevens MV, Akter MH, Rusk SE, Huang RJ, Cohen A, Noguchi A, Springer D, Bocharov AV, Eggerman TL, Suen DF, Youle RJ, Amar M, Remaley AT, Sack MN. Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. *The Journal of clinical investigation*. 2011; 121:3701–3712. [PubMed: 21865652]
219. Zhang C, Lin M, Wu R, Wang X, Yang B, Levine AJ, Hu W, Feng Z. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108:16259–16264. [PubMed: 21930938]
220. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. *Nature cell biology*. 2010; 12:119–131. [PubMed: 20098416]
221. Deng H, Dodson MW, Huang H, Guo M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in *Drosophila*. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105:14503–14508. [PubMed: 18799731]
222. Suen DF, Narendra DP, Tanaka A, Manfredi G, Youle RJ. Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic hybrid cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107:11835–11840. [PubMed: 20547844]
223. Sun X, Liu M, Hao J, Li D, Luo Y, Wang X, Yang Y, Li F, Shui W, Chen Q, Zhou J. Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation. *Cell cycle*. 2013; 12:1133–1141. [PubMed: 23470638]
224. Tay SP, Yeo CW, Chai C, Chua PJ, Tan HM, Ang AX, Yip DL, Sung JX, Tan PH, Bay BH, Wong SH, Tang C, Tan JM, Lim KL. Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. *The Journal of biological chemistry*. 2010; 285:29231–29238. [PubMed: 20630868]
225. Poulgiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC, Wyllie AH, Adams DJ, Arends MJ. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107:15145–15150. [PubMed: 20696900]
226. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science*. 2004; 304:1158–1160. [PubMed: 15087508]

227. Rakovic A, Grunewald A, Seibler P, Ramirez A, Kock N, Orolicki S, Lohmann K, Klein C. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. *Human molecular genetics*. 2010; 19:3124–3137. [PubMed: 20508036]
228. Wood-Kaczmar A, Gandhi S, Yao Z, Abramov AY, Miljan EA, Keen G, Stanyer L, Hargreaves I, Klupsch K, Deas E, Downward J, Mansfield L, Jat P, Taylor J, Heales S, Duchon MR, Latchman D, Tabrizi SJ, Wood NW. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. *PloS one*. 2008; 3:e2455. [PubMed: 18560593]
229. Wang HL, Chou AH, Wu AS, Chen SY, Weng YH, Kao YC, Yeh TH, Chu PJ, Lu CS. PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. *Biochimica et biophysica acta*. 2011; 1812:674–684. [PubMed: 21421046]
230. Gautier CA, Kitada T, Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105:11364–11369. [PubMed: 18687901]
231. Petit A, Kawarai T, Paitel E, Sanjo N, Maj M, Scheid M, Chen F, Gu Y, Hasegawa H, Salehi-Rad S, Wang L, Rogaeva E, Fraser P, Robinson B, St George-Hyslop P, Tandon A. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. *The Journal of biological chemistry*. 2005; 280:34025–34032. [PubMed: 16079129]
232. Wang HL, Chou AH, Yeh TH, Li AH, Chen YL, Kuo YL, Tsai SR, Yu ST. PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c. *Neurobiology of disease*. 2007; 28:216–226. [PubMed: 17707122]
233. Haque ME, Thomas KJ, D'Souza C, Callaghan S, Kitada T, Slack RS, Fraser P, Cookson MR, Tandon A, Park DS. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105:1716–1721. [PubMed: 18218782]
234. Benard G, Karbowski M. Mitochondrial fusion and division: Regulation and role in cell viability. *Seminars in cell & developmental biology*. 2009; 20:365–374. [PubMed: 19530306]
235. Soubannier V, McBride HM. Positioning mitochondrial plasticity within cellular signaling cascades. *Biochimica et biophysica acta*. 2009; 1793:154–170. [PubMed: 18694785]
236. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. *Nature*. 2006; 441:1162–1166. [PubMed: 16672981]
237. McLelland GL, Soubannier V, Chen CX, McBride HM, Fon EA. Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. *The EMBO journal*. 2014; 33:282–295. [PubMed: 24446486]
238. Cali T, Ottolini D, Brini M. Calcium and endoplasmic reticulum-mitochondria tethering in neurodegeneration. *DNA and cell biology*. 2013; 32:140–146. [PubMed: 23477673]
239. Gandhi S, Wood-Kaczmar A, Yao Z, Plun-Favreau H, Deas E, Klupsch K, Downward J, Latchman DS, Tabrizi SJ, Wood NW, Duchon MR, Abramov AY. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. *Molecular cell*. 2009; 33:627–638. [PubMed: 19285945]
240. Deas E, Piipari K, Machhada A, Li A, Gutierrez-del-Arroyo A, Withers DJ, Wood NW, Abramov AY. PINK1 deficiency in b-cells increases basal insulin secretion and improves glucose tolerance in mice. *Open biology*. 2014; 4:140051.
241. Yao Z, Gandhi S, Burchell VS, Plun-Favreau H, Wood NW, Abramov AY. Cell metabolism affects selective vulnerability in PINK1-associated Parkinson's disease. *Journal of cell science*. 2011; 124:4194–4202. [PubMed: 22223879]
242. Akundi RS, Zhi L, Sullivan PG, Bueler H. Shared and cell type-specific mitochondrial defects and metabolic adaptations in primary cells from PINK1-deficient mice. *Neuro-degenerative diseases*. 2013; 12:136–149. [PubMed: 23295771]
243. Unoki M, Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. *Oncogene*. 2001; 20:4457–4465. [PubMed: 11494141]

244. Mei Y, Zhang Y, Yamamoto K, Xie W, Mak TW, You H. FOXO3a-dependent regulation of Pink1 (Park6) mediates survival signaling in response to cytokine deprivation. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106:5153–5158. [PubMed: 19276113]
245. Michiorri S, Gelmetti V, Giarda E, Lombardi F, Romano F, Marongiu R, Nerini-Molteni S, Sale P, Vago R, Arena G, Torosantucci L, Cassina L, Russo MA, Dallapiccola B, Valente EM, Casari G. The Parkinson-associated protein PINK1 interacts with Beclin1 and promotes autophagy. *Cell death and differentiation*. 2010; 17:962–974. [PubMed: 20057503]
246. Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. *Cancer research*. 2008; 68:2551–2556. [PubMed: 18413720]
247. Akundi RS, Zhi L, Bueler H. PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis. *Neurobiology of disease*. 2012; 45:469–478. [PubMed: 21945539]
248. Taguchi N, Ishihara N, Jofuku A, Oka T, Mihara K. Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. *The Journal of biological chemistry*. 2007; 282:11521–11529. [PubMed: 17301055]
249. Kashatus DF, Lim KH, Brady DC, Pershing NL, Cox AD, Counter CM. RALA and RALBP1 regulate mitochondrial fission at mitosis. *Nature cell biology*. 2011; 13:1108–1115. [PubMed: 21822277]
250. Mitra K, Wunder C, Roysam B, Lin G, Lippincott-Schwartz J. A hyperfused mitochondrial state achieved at G1-S regulates cyclin E buildup and entry into S phase. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106:11960–11965. [PubMed: 19617534]
251. Smirnova E, Griparic L, Shurland DL, van der Bliek AM. Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells. *Molecular biology of the cell*. 2001; 12:2245–2256. [PubMed: 11514614]
252. Yamano K, Youle RJ. Coupling mitochondrial and cell division. *Nature cell biology*. 2011; 13:1026–1027. [PubMed: 21892144]
253. O’Flanagan CH, Morais VA, Wurst W, De Strooper B, O’Neill C. The Parkinson’s gene PINK1 regulates cell cycle progression and promotes cancer-associated phenotypes. *Oncogene*. 2015; 34:1363–1374. [PubMed: 24681957]
254. Bonda DJ, Bajic VP, Spremo-Potparevic B, Casadesus G, Zhu X, Smith MA, Lee HG. Review: cell cycle aberrations and neurodegeneration. *Neuropathology and applied neurobiology*. 2010; 36:157–163. [PubMed: 20059701]
255. Herrup K, Yang Y. Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? *Nature reviews. Neuroscience*. 2007; 8:368–378. [PubMed: 17453017]
256. Herrup K. The involvement of cell cycle events in the pathogenesis of Alzheimer’s disease. *Alzheimer’s research & therapy*. 2010; 2:13.
257. Staropoli JF. Tumorigenesis and neurodegeneration: two sides of the same coin? *BioEssays : news and reviews in molecular, cellular and developmental biology*. 2008; 30:719–727.
258. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meo G, van Duijn CM, Oostra BA, Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science*. 2003; 299:256–259. [PubMed: 12446870]
259. Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, Cookson MR. The Parkinson’s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. *Proceedings of the National Academy of Sciences of the United States of America*. 2004; 101:9103–9108. [PubMed: 15181200]
260. Ashley AK, Hanneman WH, Katoh T, Moreno JA, Pollack A, Tjalkens RB, Legare ME. Analysis of targeted mutation in DJ-1 on cellular function in primary astrocytes. *Toxicology letters*. 2009; 184:186–191. [PubMed: 19063952]

261. Junn E, Jang WH, Zhao X, Jeong BS, Mouradian MM. Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. *Journal of neuroscience research*. 2009; 87:123–129. [PubMed: 18711745]
262. Blackinton J, Lakshminarasimhan M, Thomas KJ, Ahmad R, Greggio E, Raza AS, Cookson MR, Wilson MA. Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. *The Journal of biological chemistry*. 2009; 284:6476–6485. [PubMed: 19124468]
263. Kwon HJ, Heo JY, Shim JH, Park JH, Seo KS, Ryu MJ, Han JS, Shong M, Son JH, Kweon GR. DJ-1 mediates paraquat-induced dopaminergic neuronal cell death. *Toxicology letters*. 2011; 202:85–92. [PubMed: 21300143]
264. Giaime E, Yamaguchi H, Gautier CA, Kitada T, Shen J. Loss of DJ-1 does not affect mitochondrial respiration but increases ROS production and mitochondrial permeability transition pore opening. *PloS one*. 2012; 7:e40501. [PubMed: 22792356]
265. Yokota T, Sugawara K, Ito K, Takahashi R, Ariga H, Mizusawa H. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. *Biochemical and biophysical research communications*. 2003; 312:1342–1348. [PubMed: 14652021]
266. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. *EMBO reports*. 2004; 5:213–218. [PubMed: 14749723]
267. Kriebel G, Ruckerbauer S, Burbulla LF, Kieper N, Maurer B, Waak J, Wolburg H, Gizatullina Z, Gellerich FN, Voitalla D, Riess O, Kahle PJ, Proikas-Cezanne T, Kruger R. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. *PloS one*. 2010; 5:e9367. [PubMed: 20186336]
268. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C, Tong Y, Martella G, Tscherter A, Martins A, Bernardi G, Roth BL, Pothos EN, Calabresi P, Shen J. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. *Neuron*. 2005; 45:489–496. [PubMed: 15721235]
269. Kim RH, Smith PD, Aleyasin H, Hayley S, Mount MP, Pownall S, Wakeham A, You-Ten AJ, Kalia SK, Horne P, Westaway D, Lozano AM, Anisman H, Park DS, Mak TW. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and oxidative stress. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102:5215–5220. [PubMed: 15784737]
270. Yang W, Chen L, Ding Y, Zhuang X, Kang UJ. Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. *Human molecular genetics*. 2007; 16:2900–2910. [PubMed: 17823202]
271. Waanders LF, Chwalek K, Monetti M, Kumar C, Lammert E, Mann M. Quantitative proteomic analysis of single pancreatic islets. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106:18902–18907. [PubMed: 19846766]
272. Inberg A, Linial M. Protection of pancreatic beta-cells from various stress conditions is mediated by DJ-1. *The Journal of biological chemistry*. 2010; 285:25686–25698. [PubMed: 20516060]
273. Shi SY, Lu SY, Sivasubramaniyam T, Revelo XS, Cai EP, Luk CT, Schroer SA, Patel P, Kim RH, Bombardier E, Quadriatero J, Tupling AR, Mak TW, Winer DA, Woo M. DJ-1 links muscle ROS production with metabolic reprogramming and systemic energy homeostasis in mice. *Nature communications*. 2015; 6:7415.
274. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron*. 2004; 44:595–600. [PubMed: 15541308]
275. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Miyhok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron*. 2004; 44:601–607. [PubMed: 15541309]

276. Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, Barone P. Apoptotic mechanisms in mutant LRRK2-mediated cell death. *Human molecular genetics*. 2007; 16:1319–1326. [PubMed: 17409193]
277. Niu J, Yu M, Wang C, Xu Z. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein. *Journal of neurochemistry*. 2012; 122:650–658. [PubMed: 22639965]
278. Mortiboys H, Johansen KK, Aasly JO, Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. *Neurology*. 2010; 75:2017–2020. [PubMed: 21115957]
279. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102:18676–18681. [PubMed: 16352719]
280. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, Faull RL, Emson PC, Torp R, Ottersen OP, Dawson TM, Dawson VL. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. *Annals of neurology*. 2006; 60:557–569. [PubMed: 17120249]
281. Nikonova EV, Xiong Y, Tanis KQ, Dawson VL, Vogel RL, Finney EM, Stone DJ, Reynolds IJ, Kern JT, Dawson TM. Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity. *Human molecular genetics*. 2012; 21:163–174. [PubMed: 21972245]
282. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB. International Parkinson's Disease Genomics, C., Parkinson's Study Group Parkinson's Research: The Organized, G. I., andMe, GenePd, NeuroGenetics Research, C., Hussman Institute of Human, G., Ashkenazi Jewish Dataset, I., Cohorts for, H., Aging Research in Genetic, E., North American Brain Expression, C., United Kingdom Brain Expression, C., Greek Parkinson's Disease, C., Alzheimer Genetic Analysis, G. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nature genetics*. 2014; 46:989–993. [PubMed: 25064009]
283. Schultheis PJ, Hagen TT, O'Toole KK, Tachibana A, Burke CR, McGill DL, Okunade GW, Shull GE. Characterization of the P5 subfamily of P-type transport ATPases in mice. *Biochemical and biophysical research communications*. 2004; 323:731–738. [PubMed: 15381061]
284. Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, Caldwell KA, Caldwell GA, Cooper AA, Rochet JC, Lindquist S. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. *Nature genetics*. 2009; 41:308–315. [PubMed: 19182805]
285. Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D. Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2012; 32:4240–4246. [PubMed: 22442086]
286. Park JS, Koentjoro B, Veivers D, Mackay-Sim A, Sue CM. Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction. *Human molecular genetics*. 2014; 23:2802–2815. [PubMed: 24399444]
287. Gusdon AM, Zhu J, Van Houten B, Chu CT. ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. *Neurobiology of disease*. 2012; 45:962–972. [PubMed: 22198378]
288. Behrens MI, Bruggemann N, Chana P, Venegas P, Kagi M, Parrao T, Orellana P, Garrido C, Rojas CV, Hauke J, Hahnen E, Gonzalez R, Seleme N, Fernandez V, Schmidt A, Binkofski F, Kompf D, Kubisch C, Hagenah J, Klein C, Ramirez A. Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations. *Movement disorders : official journal of the Movement Disorder Society*. 2010; 25:1929–1937. [PubMed: 20683840]
289. Tan EK, Ho P, Tan L, Prakash KM, Zhao Y. PLA2G6 mutations and Parkinson's disease. *Annals of neurology*. 2010; 67:148. [PubMed: 20186954]

290. Giovannone B, Tsiaras WG, de la Monte S, Klysik J, Lautier C, Karashchuk G, Goldwurm S, Smith RJ. GIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signaling. *Human molecular genetics*. 2009; 18:4629–4639. [PubMed: 19744960]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Highlights

- Neuronal management of energetic status in Parkinson's Disease (PD) is reviewed
- Mitochondria, endoplasmic reticulum and lysosomes involvement in PD are discussed
- Mitochondrial dysfunction leads to neuronal metabolic re-programming in PD
- Increased neuronal glycolysis shifts down pentose-phosphate pathway (PPP) in PD
- Down-regulation of PPP in neurons may account for PD-associated oxidative stress

Figure 1. Cellular pathways associated with bioenergetics in PD

Genetic mutations in PD-related genes and/or exposure to environmental toxins lead to an increased oxidative stress and mitochondrial failure that affect several metabolic pathways. Dysfunctional mitochondria induce the aggregation of proteins, such as α -synuclein, due to impairment in the ubiquitin/proteasome and autophagy/lysosome pathways. This also leads to alterations in the cross-talk between mitochondria and ER, contributing to increased mROS. Additional factors, such as dopamine metabolism or glial activation may also contribute to increased ROS. Excessive ROS interfere with ATP synthesis and contribute to the stabilization of proteins, such as HIF-1, which mediates glycolytic up-regulation in order to compensate for the mitochondrial energy impairment. However, increased glycolysis may have adverse effects in neurons. Thus, glycolysis facilitates a failed attempt of post-mitotic cells to re-enter the cell cycle, a feature that may be important in genetic PD-related mutations affecting p53. Also, certain glycolytic intermediates may interact with dopamine derivatives generating neurotoxins. Finally, increased glycolysis impairs antioxidant PPP. Thus, the compensative increase in glycolysis contributes to the cascade of events leading to selective degeneration of dopaminergic neurons.

Figure 2. Metabolic shift in familial parkinsonism

Mutations in familial PD-linked genes encoding α -synuclein, parkin, DJ-1, PINK1 and LRRK2 are associated with PD pathogenesis. These mutations contribute to PD causing mitochondrial dysfunction, oxidative damage and abnormal protein aggregation and phosphorylation, compromising neuronal function and survival. α -Synuclein undergoes aggregation as a consequence of its mutation or indirectly by mutation of other PD-related genes, endangering protein degradation pathways and inducing ER stress and mitochondrial dysfunction. Mitochondrial dysfunction and oxidative damage lead to deficits in ATP, which activates glycolysis. This glycolytic increase can also be consequence of genetic mutations in Parkin, PINK1 and DJ-1, which act on specific glycolytic regulatory proteins. In addition, Parkin, being an E3 ubiquitin ligase, promotes proteasomal degradation, participates in mitochondrial fusion and fission processes, and reverses PINK1-induced mitochondrial dysfunction. DJ-1 protects mitochondria against oxidative stress, it functions as a transcriptional co-activator of PINK1, amongst others, and blocks α -synuclein aggregation. PINK1 protects against mitochondrial dysfunction, preventing mitochondrial ROS production and recruiting Parkin into mitochondria, thus controlling mitochondrial dynamics. LRRK2 seems to play a role in synaptic vesicles formation. LRRK2 causes abnormal protein phosphorylation, which induces mitochondrial-dependent cell death. Furthermore, familial PD-linked genes such as Parkin, PINK1, DJ-1 and α -synuclein favour ER-mitochondria crosstalk through maintenance of contact sites, thus promoting cell survival (Green arrows indicate activating effects, and red lines with blunt ends inhibitory effects).